Mitochondrial Management of Reactive Oxygen Species

Gaetana Napolitano 1, Gianluca Fasciolo 2 and Paola Venditti 2,*

Abstract: Mitochondria in aerobic eukaryotic cells are both the site of energy production and the formation of harmful species, such as radicals and other reactive oxygen species, known as ROS. They contain an efficient antioxidant system, including low-molecular-mass molecules and enzymes that specialize in removing various types of ROS or repairing the oxidative damage of biological molecules. Under normal conditions, ROS production is low, and mitochondria, which are their primary target, are slightly damaged in a similar way to other cellular compartments, since the ROS released by the mitochondria into the cytosol are negligible. As the mitochondrial generation of ROS increases, they can deactivate components of the respiratory chain and enzymes of the Krebs cycle, and mitochondria release a high amount of ROS that damage cellular structures. More recently, the feature of the mitochondrial antioxidant system, which does not specifically deal with intramitochondrial ROS, was discovered. Indeed, the mitochondrial antioxidant system detoxifies exogenous ROS species at the expense of reducing the equivalents generated in mitochondria. Thus, mitochondria are also a sink of ROS. These observations highlight the importance of the mitochondrial antioxidant system, which should be considered in our understanding of ROS-regulated processes. These processes include cell signaling and the progression of metabolic and neurodegenerative disease.

Keywords: oxygen consumption; OxPhos; ROS generation; ROS removal; enzymatic antioxidants; low-molecular-weight antioxidants

1. Introduction

Mitochondria are double-membrane organelles located in the cells of most eukaryotic organisms, where they perform a wide range of important functions. They contribute to the regulation of intracellular calcium concentration and control the oxidation of fatty acids, as well as being involved in the metabolism of steroids and some amino acids, and the synthesis of urea and phospholipids. However, their main function is to provide most of the energy required for cellular endergonic reactions, such as the synthesis of adenosine 5′-triphosphate (ATP) by the electron transport chain (ETC) and oxidative phosphorylation. This explains why a disturbance of mitochondrial function, due to damage of the mitochondrial components, can cause an impairment of cellular function and even cell death.

The electron flux along the mitochondrial respiratory chain also determines the production of oxygen radicals and other reactive species, referred to as reactive oxygen species (ROS) [1]. ROS include species that are highly reactive, such as the hydroxyl radical (•OH), and species with a low reactivity, such as the superoxide (O2•−) and hydrogen peroxide (H2O2). ROS can oxidize and damage cellular components, including mitochondria, altering their functionality.

Mitochondria produce ROS at a rate that depends on cellular pathophysiological conditions and is low under normal conditions. However, mitochondrial antioxidant systems, composed of enzymatic and non-enzymatic antioxidants [2], largely remove ROS produced by mitochondria.
Under conditions where ROS production increases beyond mitochondrial antioxidant capacity, some components of the mitochondrial electronic chain, or Krebs cycle enzymes, may be deactivated. In these conditions, ROS reaching the cytosol also increase, and can be neutralized here by the antioxidant system of the cell or can damage the cellular components [3].

Several sources of ROS are present in the cell, but mitochondria are considered to be their main source [4].

Extensive experimental evidence indicates that the systems that evolved to protect mitochondria against endogenously produced ROS can also scavenge ROS produced from other cellular sources. [5]. This observation indicates that mitochondria can act as an intracellular sink for ROS, which contrasts with the usually recognized role of the organelles as ROS producers.

However, under which conditions and which part of the mitochondrial population performs a sink function is not yet established. In this review, we analyze the role of mitochondria as an energy source and in ROS generation. We then describe the mitochondrial systems involved in ROS removal. Finally, we analyze the current knowledge on how the mitochondrial antioxidant system can remove ROS produced by other cellular sources.

2. Mitochondria as Source of Metabolic Energy Production

2.1. Mitochondria and ATP Synthesis

The Krebs cycle plays a crucial role in the energy transduction process that leads to the generation of ATP (Figure 1). The acetyl groups resulting from the catabolism of lipids, carbohydrates and proteins converge in acetyl-coenzyme A. The Krebs cycle leads to the oxidation of the carbon atoms of the acetyl-coenzyme A acetyl groups, converting them into CO$_2$ and transferring electrons to the nicotinamide adenine dinucleotide (NAD$^+$) and flavin adenine dinucleotide (FAD). The reduced forms of these molecules (NADH and FADH$_2$) are reoxidized by the transfer of electrons to the mitochondrial complexes of the mitochondrial electron chain and, eventually, to oxygen in a multi-stage process, in which the energy, resulting from the decrease in the potential of electrons, is gradually released.

Complex I (NADH-ubiquinone oxidoreductase) consists of 46 different subunits and including a flavoprotein and six iron-sulfur centers [6]. It is L-shaped, the long arm is an integral membrane protein, and the short arm protrudes into the matrix and contains the active centers FMN and NADH [7].

Complex II (succinate-ubiquinone reductase) is a component of both the Krebs cycle and the mitochondrial respiratory chain. It is an integral protein with covalently linked FAD and iron-sulfur centers in the extrinsic domain of the membrane [8].

Complex III (ubiquinol-cytochrome c oxidoreductase) is a dimer with each monomer, consisting of 11 subunits. The redox centers, the hemes b562, b566 and c1 and the cluster [2Fe-2S], are associated with 3 of the 11 subunits of each monomer [9].

The final catalyst of the electron chain is the complex IV, the cytochrome c-O$_2$ oxidoreductase (COX). COX is a large integral membrane protein which contains two hemes, cytochrome a and cytochrome a3, and two copper centers, the CuA and CuB centers [10].

Parts of the mitochondrial respiratory chain complexes form an ordered structure called “supercomplex” [11], which plays important role in efficient energy production [12], the stabilization of complex I [13], and the prevention of ROS generation [14].

Electrons transfer from NADH and succinate to Complex I and Complex II, respectively. Subsequently, complexes I and II transfer electrons to ubiquinone. This latter is a fat-soluble benzoquinone, which possesses a long isoprenoid side chain that is laterally diffusible in the phospholipid layers of the inner membrane. Electrons pass from ubiquinone through Complex III to cytochrome c (Cytc). Cytochrome c is another mobile vector weakly connected to the outer surface of the inner mitochondrial membrane by electrostatic interactions; it interacts with the cytochrome c1 of Complex III and accepts electrons [15].
Figure 1. Schematic representation of the mitochondrial involvement in the catabolism of lipids carbohydrates and proteins and ATP production. ETC: electron transport chain. ATP: adenosine triphosphate.

Reduced cytochrome c moves along the membrane surface and interacts with Complex IV subunit II by electrostatic interactions, simultaneously transmitting electrons from Complex III to CuA in Complex IV. The latter removes an electron from four reduced cytochrome c molecules (Fe$^{2+}$-heme) by oxidizing them to Fe$^{3+}$-cytochrome c. It then transfers the four electrons to the oxygen, which is the final acceptor of the electrons. Therefore, oxygen forms water by a tetravalent reduction.

The flow of electrons from the electron donor, NADH or succinate, to the acceptor, O$_2$, occurs due to the oxidation potential of the components in the electron transfer chain. Electrons move to compounds with more positive oxidation potentials. The chemical energy released by the decrease in the redox potential of electrons passing through the respiratory complexes serves to pump protons from the mitochondrial matrix to the intermembrane space. In this way, a proton motor force consisting of an electric ($\Delta \Psi_m$) and proton ($\Delta \text{pH}$) gradient [16] is created.

The process by which this force brings protons back into the matrix via the fifth mitochondrial complex (Complex V, ATP synthase), resulting in the synthesis of ATP, is called oxidative phosphorylation (OxPhos) [17].

The ADP/ATP translocase or adenine nucleotide translocator (ANT) exports the ATP to the cytosol to do useful “work” in the cell [18].

2.2. Regulation of OxPhos Activity

Due to its essential role, OxPhos is finely tuned for the optimal functioning of an organism (Figure 2). Cytc and COX are the respiratory components primarily involved in regulation. Indeed, in intact mammalian cells, the electron transfer reaction from Cytc to oxygen through COX is the limiting phase of the electron transport chain under physiological conditions [19,20]. This step is also tightly regulated. Indeed, several regulatory mechanisms, including the allosteric regulation of COX and Cytc (e.g., by the ATP/ADP
ratio) and reversible post-translational changes, including phosphorylation, were demonstrated [21,22].

Figure 2. Schematic overview of the main factors involved in OXPHOS regulation. NO, nitric oxide; Cox, cytochrome oxidase; Cytc, cytochrome C. ATP: Adenosine triphosphate. ADP: Adenosine diphosphate.

Three metabolites, O$_2$, NO, and ADP, appear as the main regulators of OxPhos function. In blood vessels, NO produces vasodilation and increases blood flow and the release of O$_2$ to tissues [23]. In mitochondria, NO inhibits respiration through a rapid and reversible inhibition of COX [24]. NO binds to the O$_2$ site of the a3 domain of the heme of cytochrome oxidase in the reduced state, competing with O$_2$ [25]. Therefore, NO significantly increases the O$_2$ concentration at which the O$_2$ absorption rate is semi-maximum [26]. This effect allows for the redistribution of oxygen in sites where the O$_2$ concentration is low and can be a mechanism for preserving areas with critical oxygen levels [27].

The energy requirements, expressed as cytosolic ADP concentration or phosphorylation potential ([ATP]/[ADP] +Pi), determine the cellular rates of respiration and ATP synthesis. As cellular energy demand increases, the breakdown of ATP into ADP and Pi increases, and the phosphorylation potential decreases. With more ADP available, the rate of respiration increases, causing ATP to regenerate.

The dependence of the respiratory rate on the concentration of ADP is appointed as a respiratory control or acceptor control. Mitochondrial respiration in the presence of a respiratory substrate but without ADP is called “controlled respiration” or “at rest” (State 4). The respiration with both the respiratory substrate and ADP is called “active respiration” (State 3) [28]. The rate of the respiration of the mitochondria isolated from
several tissues is 5 to 8 times higher in State 3 than in State 4. Therefore, the respiratory control ratio (RCR) assumes a value between 5 and 8.

ATP acts as a negative feedback inhibitor of the interaction between Cytc and COX through binding to both proteins, and thus regulating the speed of the electron flux [29]. The allosteric inhibition exhibited by ATP uncompetitively acts by transforming the high-affinity Cytc–COX binding site into a low-affinity site [30]. Arg91 is the amino acid of Cytc involved in ATP binding. When ATP occupies this site, the electron transfer activity of Cytc significantly reduces [31]. This effect is likely due to structural changes in both proteins and electrostatic changes when ATP, negatively charged, binds to Cytc and COX. Therefore, the activity of the electron transport chain is adapted to the energy demand through the ATP/ADP ratio as an intrinsic measure of the energy state of the cell.

Another regulatory mechanism, mediated by phosphorylation, was discovered in Cytc, isolated from the cardiac [32] and liver [33] tissues of cows, under conditions in which the state of in vivo physiological phosphorylation was preserved. Cytc tyrosine phosphorylation was found in both tissues, but cardiac Cytc was phosphorylated on Tyr97 [32], while hepatic Cytc was phosphorylated on Tyr48 [33]. The phosphorylation of both tyrosine residues resulted in the partial inhibition of the reaction with the isolated COX leading to the control of respiration. Since then, it was corroborated that the phosphorylation of Cytc occurred in a highly tissue-specific way [21]. Thr28 phosphorylation of Cytc was mapped in the bovine kidney [34], and a second phosphorylation site, Thr58, was subsequently identified in the rat kidney [35]. Ser47 was mapped in rat and pig brains under basal conditions [36], while Tyr97 was mapped in post-insulin treatment in rat and pig brains [37]. These phosphorylations of Cytc also lead to functional changes, including altered reaction kinetics with COX.

Cytc is a small protein, and this could explain why its modifications, even if not directly part of the COX interaction site, according to crystallographic data, can affect or interfere with the optimal Cytc–COX binding. For example, the Cytc and COX interaction is mainly mediated by electrostatic interactions of positively charged lysine residues on Cytc and negatively charged COX residues, in addition to hydrophobic interactions across the binding interface [38]. Therefore, depending on their specific position on Cytc, the introduction of negative charges after phosphorylation can affect and interfere with the optimal binding of Cytc to COX and reduce the reaction rate.

3. Mitochondria as Sources of ROS

More than 50 years have passed since the mitochondrial generation of H₂O₂ in the presence of respiratory substrates was discovered [39]. A few years later, it was discovered that mitochondria contain superoxide dismutase (SOD) [40] and produce O₂⁻• [41]. These findings suggested that mitochondria produce H₂O₂ by the dismutation of O₂⁻•.

In mammalian mitochondria, the genesis of most of the produced ROS involves the same electron transfer pathways implicated in the oxidation of nutrients and ATP biosynthesis. In fact, under physiological conditions, a small part of the electrons in the electron transport chain does not follow the usual transfer order but exits directly from the ETC and interacts with O₂ to produce O₂⁻• through a univalent reduction.

3.1. Sites of ROS Production

The ROS produced during the tetravalent reduction of O₂ by cytochrome oxidase are not released into the surrounding medium. Conversely, the superoxide generated by the auto-oxidation of carriers of other respiratory complexes is released into the surrounding medium. For a long time, evidence was provided that secondary O₂ reaction sites localized in Complex I [42,43] and Complex III [44]. Only several years later, it was reported that potential ROS production sites localize in mitochondrial Complex II [45,46] and in various mitochondrial enzymatic components, as well as components of the respiratory chain [47,48]. However, the exact sites of ROS generation and their relative contribution in vivo remains an unsolved problem.
To date, eleven different sites involved in oxidation and electron transport have been identified as ROS producers in mammalian mitochondria [49]. These sites give electrons to oxygen to produce superoxide or hydrogen peroxide. However, it is not well established if a site transfers one electron to oxygen to generate a superoxide radical or two electrons to generate hydrogen peroxide, or both of these.

The electron flow from metabolites to $O_2$ occurs because of the oxidation potential of the mitochondrial components. The electrons flow into the NADH/NAD$^+$ pool via the NAD-bound dehydrogenases. The 2-oxoacid dehydrogenase complexes catalyze the oxidative decarboxylation of several 2-oxoacids to acyl-CoA and NADH. The 2-oxoacid dehydrogenase complexes comprise: (1) 2-oxoglutarate dehydrogenase (OF site) [50], (2) pyruvate dehydrogenase (PF site) [50], (3) branched-chain 2-oxoacid dehydrogenase (site BF) [50], and (4) aminoadipate dehydrogenase (site AF) [51]. The dihydrolipoamide dehydrogenase of each complex contains a FAD, a powerful electron leak site, which can generate superoxide/hydrogen peroxide. The 2-oxoacid dehydrogenase complexes exclusively generate superoxide and/or hydrogen peroxide in the matrix space being localized in the mitochondrial matrix or loosely attached to the inner face of the inner membrane.

The electrons pass from the NADH to the flavin-containing site (site IF) of Complex I and then through the quinone-binding site (site I$Q$) to the ubiquinone-bound dehydrogenase pool. The I$F$ site generates superoxide [52,53] exclusively into the matrix space [52]. The localization of the I$F$ site near the tip of the hydrophilic arm of complex I [54], which protrudes into the mitochondrial matrix, accounts for superoxide release into the matrix.

The I$Q$ site generates most of the superoxide/hydrogen peroxide when succinate or glycerol 3-phosphate drive oxygen consumption. In this case, the generation of superoxide/hydrogen peroxide depends on the reverse transport of electrons. In this phenomenon, the high ubiquinol/ubiquinone ratio (QH$_2$/Q), and the high protonmotive force, due to the electron transfer through complexes III and IV, push electrons into Complex I against the redox potential [55].

Ubiquinone-bound dehydrogenases transfer electrons to the pool of QH$_2$/Q. These dehydrogenases are (1) the site G$_Q$ (mitochondrial glycerol-3-phosphate dehydrogenase), (2) the site E$_F$ (electron-transfer flavoprotein (ETF): Q oxidoreductase system), (3) the site D$_F$ (dihydroorotate dehydrogenase), and (4) the site II$F$ (complex II).

Site II$F$ produces a negligible amount of ROS in normal conditions. This amount increases in disease related to the Complex II mutation mainly due to the site IIF [56]. Site II$F$ releases ROS exclusively in the matrix because the flavoprotein localizes on the matrix side of the inner mitochondrial membrane [50].

From QH$_2$, the electrons transfer to the outer Q-binding site of complex III (site III$Q_o$). After that, they pass to the center III$Q_i$ in the Q-cycle through cytochrome b566 and to oxygen through the cytochrome c and complex IV.

The III$Q_o$ site [57] generates superoxide. It locates on the outer side of complex III [58], and releases superoxide both in the matrix and in the intermembrane space [58].

### 3.2. Regulation of ROS Production

The reaction of superoxide formation is of second order since its rate ($d[O_2^{•−}] / dt$) depends on the product of two factors: the local concentration of $O_2$ and the concentration of the electron carriers capable of transferring an electron at $O_2$, generating $O_2^{•−}$; in reduced form, ($R^*$) (autoxidizable carrier). The latter, for its part, depends on the concentration of the electron carriers ($C$) and their fraction in the reduced form ($F$):

$$d[O_2^{•−}] / dt = k \cdot [O_2] \cdot [R^*]$$

Another factor affecting the reaction rate is the rate constant ($k$) for the reaction between electron carrier and $O_2$, which has the dimensions of the inverse of the product of concentration and time.

The concentration of mitochondrial carriers responsible for $O_2^{•−}$ production varies according to animal species, tissue, age, and hormonal state [59]. This may underlie
many of the differences in maximum ROS production rates between tissues. Thus, a high concentration of complex I in rat heart mitochondria compared to pigeon heart mitochondria explains why rat mitochondria releases significantly more H$_2$O$_2$ than pigeon mitochondria [60].

Most likely, the main factor influencing of O$_2$•− production rate is the fraction of the autoxidizable carrier in the reduced form. The value of this fraction strongly depends on the rate of electron flow. Indeed, when this rate increases, F decreases and the rate of O$_2$•− also decreases. This inverse dependence of (R*) on the rate of electron flow explains the observation that the rate of O$_2$•− production during State 4 is higher than during State 3. In the presence of ADP (State 3), the electrochemical gradient on both sides of the mitochondrial inner membrane is dissipated through the ATP synthetase complex leading to ATP synthesis. The rate of electron flow is high, whereas both the F value and rate of O$_2$•− are low. In the absence of ADP (State 4), the flux of H$^+$ through the ATP synthetase stops. In this condition, the gradient of H$^+$ increases, the electron flow slows down and the reduction degree of the respiratory chain and the generation of superoxide increases.

A lowering of electrochemical gradient can also be obtained by inducing a small proton leak through the inner mitochondrial membrane, which stimulates oxygen consumption and, in parallel, decreases the reduction degree of mitochondrial, autoxidizable carriers, and thus lowering the ROS production. In in vitro experiments, this phenomenon can be triggered by substances (uncouplers) that allow a rapid diffusion of protons in the mitochondrial matrix, thus causing an acceleration of the electronic flow.

The regulated, moderate (“mild”) uncoupling of mitochondrial oxidative phosphorylation was suggested as a feasible therapeutic strategy for the regulation of the intracellular and intramitochondrial ROS level [61].

Fatty acids are mild natural uncouplers [62]. In their protonated form, they can cross the mitochondrial inner membrane followed by deprotonation in the matrix side. The anionic form of the fatty acid completes the cycle by returning to the cytosolic side.

Mitochondrial uncoupling proteins (UCPs) were considered as potential mild uncouplers. The relationship between ROS production and UCPs activity was revealed in 1997 in experiments where GDP, an inhibitor of UCP1, caused an increase in ΔΨ and ROS production [63].

Different from the uncouplers, the presence in in vitro experiments of inhibitors of the respiratory chain, such as rotenone (an inhibitor of Complex I), or antimycin (an inhibitor of Complex III) causes the carriers upstream from the site of inhibition to become fully reduced and increases the formation of O$_2$•−.

It has long been known that tissue oxygen tension is much less than that in ambient air, and that the oxygen gradient can be readily observed at the intracellular level [64].

Because the apparent K$_m$ of cytochrome oxidase for O$_2$ is very low (1 µM) [65], at low intracellular levels of oxygen, the amount of oxygen is still sufficient for saturating cytochrome oxidase and maintaining normal mitochondrial respiration [66]. Conversely, the effect of the oxygen tension on the rate of ROS production is more controversial.

Boveris and Chance [67] first demonstrated that mitochondrial ROS production enhances under hyperoxic conditions. This observation found support in previous studies, which showed that even the generation of O$_2$•− or H$_2$O$_2$ by submitochondrial particles [68] and isolated respiratory complexes [53] increased when the O$_2$ concentration increased above the usual atmospheric level of 21% O$_2$. This increase is roughly proportional to the concentration of O$_2$, at least over the lower range of its supraphysiological concentrations. The marked increase in the formation of O$_2$•− or H$_2$O$_2$ under hyperbaric conditions and its immediate onset, provided support at the molecular level for the early hypothesis that oxygen toxicity is in part a consequence of increased rates of the formation of intracellular highly reactive species [69].

Studies dealing with the effects of the decreased concentration of O$_2$ showed that isolated complex I O$_2$•− production decreases linearly with the lowered O$_2$ concentration [53], and that H$_2$O$_2$ production by isolated mitochondria decreases when the concentration of
O₂ is lowered below that of an air-saturated medium [70]. However, a subsequent study has not confirmed the above observations. Indeed, it was found that the rate of H₂O₂ production was almost unaffected by changes in an oxygen concentration ranging from 250 µM (approximately ambient oxygen) to as low as about 5–7 µM (intracellular range) and only decreased when the O₂ concentration decreased below 5 µM [71].

It was suggested that the dependence of mitochondrial ROS production on O₂ concentration may be a relevant factor in changes in ROS production in vivo. This is because the levels of extracellular O₂ change with the physiological state, and there are O₂ concentration gradients between the bloodstream and the mitochondria, at which the O₂-consuming cytochrome oxidase locally lowers O₂ levels. [72,73]. Therefore, changes in the rate of O₂ consumption by mitochondria may be an important aspect of modifying O₂•− production in vivo by altering the local O₂ concentration [72].

A substance able to modify O₂ concentration and ROS production is nitric oxide (NO). Physiological levels of NO compete with O₂ for cytochrome oxidase when O₂ concentration is low, effectively raising the apparent Km of this enzyme [74] and may, therefore, alter the levels of O₂ around mitochondria, leading to changes in O₂•− production [75,76].

The final factor affecting the rate of O₂•− production by electron carriers is the rate constant of their reaction with O₂. The reaction between protein-bound electron carriers and O₂ to form O₂•− seems to be verified through electron tunnels from the electron donor to O₂. The reaction rate depends on the distance between O₂ and the electron donor [77]. This movement is similar to that of electrons along the respiratory chain that occur by electron tunnelling from carrier to carrier, with a maximum distance of about 14 Å between each carrier for effective tunnelling to occur [78]. This distance likely forces the reaction between protein-bound electron carriers of the respiratory chain with O₂ to form O₂•−, while most of the proteins act as insulators to keep O₂ at a safe distance from the carriers, and thus minimize O₂•− production [78]. As a result, O₂•− production likely occurs at sites where O₂ can closely approach electron carriers.

The rate of electron transfer from protein-bound electron carriers to O₂ was studied for flavoenzymes that activate O₂, where the reduction of O₂ to O₂•− is often a precursor to further reactions [79]. For the flavoenzyme glucose oxidase, the rate of reduction of O₂ to H₂O₂ is \( \sim 10^6 \text{ M}^{-1} \text{s}^{-1} \) [80], and, since the rate-limiting step is the reduction of O₂ to O₂•− [80], this indicates that the production of O₂•− by electron carriers bound to protein can be rapid. Of course, the production of H₂O₂ is a consequence of the normal physiological function of glucose oxidase, and for other flavoproteins, where the electron transfer to O₂ to form O₂•− may be a side reaction, the rate varies over five orders of magnitude [81]. Even so, the rate of reduction of O₂ by the reduced FMN of complex I to form O₂•− is \( \sim 40 \text{ O}_2^{•−} \text{ min}^{-1} \) [53], corresponding to a second-order rate constant of \( \sim 10^3 \text{ M}^{-1} \text{s}^{-1} \). Thus, the k for O₂•− production as a side reaction by electron carriers bound to proteins can be rapid, although K is likely to vary greatly with the electron donor’s environment and its accessibility to O₂. Therefore, protein alterations that allow O₂ to get closer to the electron carrier, such as damage, mutations, post-translational modifications, conformational changes, or quaternary interactions, could lead to dramatic changes in the rate of O₂•− production and potentially perform a regulatory function. Such factors determining the k-value for the reaction of O₂ with protein-bound electron carriers could result in mitochondrial O₂•− production, but little is known about how k can be varied by different enzymes within mitochondria.

4. Mitochondrial Antioxidant System

In mitochondria, the antioxidant defense system articulates on various levels. In some cases, it is possible to find a preventive antioxidant system, but in all mitochondria, there is the interception system and the repair system (Figure 3).
Figure 3. Components of the antioxidant system in the mitochondria SOD2: superoxide dismutase 2; Cat: catalase; GPX1 glutathione peroxidase 1; TrxR2: thioredoxin reductase 2; Trx2: thioredoxin 2; Prx 3, 5: peroxiredoxin 3 and 5; GPX4: glutathione peroxidase 4; BER: base-excision repair; GSH: reduced glutathione; CoQ: coenzyme Q; AA: ascorbic acid.

4.1. Preventive Antioxidant System

In spermatocytes, neurons, and cardiomyocytes, all tissues with sustained metabolic activity, there is a specific type of ferritin [82] localized in the mitochondria, called mitochondrial ferritin (FtMt), which avidly sequestrates the ferrous ion [83], thus preventing the Fenton reaction-induced *OH generation [83]. FtMt is a key mitochondrial iron storage protein with a high homology to the heavy chain of cytosolic ferritin (FtH) [83–85]. FtMt has a ferroxidase activity and catalyzes the conversion of Fe^{2+} to the ferric form for storage in the FtMt spherical shell, which can accommodate up to 4000 iron atoms. It was proposed that the limited expression of FtMt to some tissue depends on its high iron affinity that could lower the iron level in the cytosol by too great an amount [83]. On the other hand, it was shown that in FtMt-overexpressing mice, the regulation of iron metabolism was not significantly modified [86], but that FtMt exerted significant protective effects under pathological conditions, such as in Alzheimer’s disease and Parkinson’s disease.

Wang et al. [87] reported that FtMt levels upregulate in the ischemic brains of mice. Moreover, mice lacking FtMt experience more severe brain damage and neurological deficits, accompanied by the typical molecular features of ferroptosis (increased lipid peroxidation) after cerebral ischemia-reperfusion (I/R), suggesting that FtMt plays a critical role in protecting against cerebral I/R [87].

4.2. Mitochondrial Interception System

4.2.1. The mitochondrial Antioxidant Enzymes

Most superoxide or hydrogen peroxide production sites release their product to the mitochondrial matrix, as they are either located in the matrix or located on the inner face of the inner membrane facing the matrix. The superoxide released into the matrix crosses the
inner membrane only slowly, so the steady-state level of the matrix superoxide depends on
the speed of production at the different sites and the rate of consumption [49].

In the matrix, the enzyme that converts the $O_2^\bullet^-$ in $H_2O_2$ is the manganese-dependent
superoxide dismutase (MnSOD), also called SOD2 [88]. This enzyme is a tetramer com-
posed of identical subunits each containing one manganese atom. The acetylation state
of the two residues of lysine regulates the activity of the enzyme through the control of
the superoxide access to the active site of the enzyme [89,90]. The acetylation of one of
these lysines inhibits the enzyme and depends on the activity of the mitochondrial elec-
tronic chain. Acetylation increases when the mitochondrial chain activity reduces [91,92].
Sirtuin-3, which requires $NAD^+$ for its function, operates deacetylation. When ETC activity
reduces, NADH accumulates and, consequently, the $NAD^+$ level reduces, which in turn
reduces Sirtuin-3-mediated SOD2 deacetylation and, therefore, SOD2 activity [93].

It was recently suggested that SOD2 broadcasts the redox signals generated by mitochon-
dria to distant sites in the cytosol, nucleus or even outside the cell [92]. In the presence of
SOD2, $O_2^\bullet^-$ is converted to $H_2O_2$ at a 2:1 ratio. $H_2O_2$ is a freely diffusible oxidant, and it has a
prominent role as a regulator of signaling systems based on redox-sensitive thiol switches.

In the intermembrane space (IMS) of higher eukaryotes there was a minor fraction (less than
5%) of the cytosolic enzyme CuZnSOD (SOD1) [94], which dismutated the released superoxide.

After cytosolic translation, a small amount of SOD1 enters the mitochondria in an
unfolded state using the outer mitochondrial membrane translocator, TOM [95]. The post-
translational modifications of SOD1 are necessary for the functionality of the enzyme but
also affect its subcellular localization. In the IMS, the copper chaperone of SOD (CCS)
causes the formation of disulfide bonds and the insertion of copper metal, thus inducing
the maturation of SOD1, which remains inside IMS [95].

The SODs-catalyzed reaction of $O_2^\bullet^-$ dismutation is in competition with the reaction
between $O_2^\bullet^-$ and $NO$•, which leads to the formation of peroxynitrite. Peroxynitrite is a
powerful biological oxidant involved in various forms of free-radical-induced tissue
damage. Thus, the SODs reaction removing $O_2^\bullet^-$ in systems containing nitric oxide
reduces the formation of the highly reactive peroxynitrite.

The reaction catalyzed by SODs with $O_2^\bullet^-$ has a rate constant near to the diffusion
control limit ($\sim 1–2 \times 10^9 \text{ M}^{-1} \text{s}^{-1}$), but the rate constant of the reaction between $O_2^\bullet^-$
and $NO$• is of one order of magnitude higher. On the other hand, the concentration of
SOD in mitochondria is high enough (about 10–20 $\mu$M in mammalian) to prevent $O_2^\bullet^-$
from reacting with $NO$•, whose level under normal conditions is very low (10–100 nM).
When $NO$• levels rise due to the overactivation of nitric oxide synthase, or the induction of
inducible nitric oxide synthase (iNOS), more peroxynitrite is generated [96] (Radi, 2018). Mitochondrial
nitrosative damage is exacerbated by the inactivation of MnSOD due to
peroxynitrite-induced nitration [96].

The importance of SOD2 for mitochondria was also established through the studies on
mice deficient in Sod2. Homozygous mutant Sod2 mice displayed neonatal lethality due to
the superoxide-induced inactivation of iron-sulfur centers in OXPHOS and citric acid
cycle enzymes [97,98]. In contrast, the heterozygous mutant Sod2 animals have a partial
OXPHOS defect involving a reduced respiratory control ratio (RCR) and an increased
propensity for the opening of the mitochondrial permeability transition pore (mtPTP) [99].

$H_2O_2$ is less reactive than superoxide; despite this, it is potentially dangerous, being
the substrate of the Fenton reaction, which produces the highly reactive hydroxyl radical.
Therefore, other enzymes are involved in $H_2O_2$ removal, including catalase and glutathione,
as well as thioredoxin peroxidase systems.

The enzyme catalase is found mainly within peroxisomes, and to a lesser extent,
in mitochondria. Until now, it was described in heart [100] liver [101], and cerebral
hippocampus [102]. Catalase breaks down two hydrogen peroxide molecules into one
molecule of oxygen [103] and two molecules of water in a two-step reaction [104]. The first
step involves the formation of an intermediate compound I (a covalent oxyferryl species
(FeIVO)) with a porphyrin $\pi$-cation radical through the reduction of one hydrogen peroxide
molecule [105]. In the second step, compound I is reduced through redox reactions by a two-electron transfer from the second molecule of hydrogen peroxide to produce the free enzyme, oxygen, and water [104].

Notwithstanding, catalase has the highest activity in decomposing the H$_2$O$_2$ in H$_2$O and O$_2$ and a low affinity for H$_2$O$_2$; therefore, it efficiently works when the inorganic hydroperoxide reach high levels [106].

It was found that the liver content of the catalase protein in the mitochondrial extracts increases with ageing, while its activity does not vary significantly. This result seems due to a significant increase in the rate of glycation that damage the enzyme, suggesting a link between glycation stress and the age-related decline in mitochondrial antioxidant defense [107].

In the cardiac mitochondria of mice, catalase contributes significantly to the consumption of H$_2$O$_2$ and is solely responsible for the removal of H$_2$O$_2$ in non-respiring or structurally damaged mitochondria [108]. Furthermore, in mice fed a high-fat diet, the mitochondrial catalase content increases by approximatively 50%, but this is not sufficient to prevent the H$_2$O$_2$-induced reduction in insulin signaling in the heart, revealed by reduced Akt phosphorylation stimulated by insulin. Thus, the selective increase in catalase does not prevent H$_2$O$_2$-induced loss in cardiac insulin signaling, indicating that mitochondrial catalase likely works to preclude the formation of high levels of H$_2$O$_2$ without perturbing redox-dependent signaling [109].

The enzymes, glutathione peroxidase (GPX) and peroxiredoxin (Prx), metabolize most of the H$_2$O$_2$. Their activities depend on the thiol groups of the residues of cysteine of reduced glutathione (GSH), and thioredoxin (Trx), respectively, to reduce the H$_2$O$_2$.

The GPXs comprise several phylogenetically related enzymes. Eight isoforms have been identified so far: the mammalian GPXs from 1 to 4 are seleno-proteins containing a selenocysteine in the catalytic center, GPX 6 is a seleno-protein only in humans and is expressed in the olfactory epithelium. GPX 5 contains cysteine instead of selenocysteine in the active center and is a secreted protein in the epididymis. GPX7 and GPX8 are cysteine-GPXs with a low GPX activity [110].

The selenol (-SeH) in seleno GPXs reacts as a selenolate with H$_2$O$_2$ to selenenic acid (-SeOH) that reduces back to -SeH by 2 GSH forming GSSG and water [111–113]. Among GPX, only GPX1 and GPX4 are found in mitochondria.

GPX1, a ubiquitously expressed homo-tetramer, is present in the cytosol and mitochondria. GPX1 is highly expressed in the mitochondria and the cytosol of the liver and kidney but poorly in the heart and muscle [114]. It works in a similar way to catalase by breaking down H$_2$O$_2$, but slowly and with a high affinity. Furthermore, it uses glutathione (GSH) as a reducing agent, which is converted into oxidized glutathione (GSSG) [115]. GPX1 reacts with hydrogen peroxide and low-molecular-mass, soluble hydroperoxides, but not with more complex lipid hydroperoxides [116] and decomposes the small quantities of peroxide that are produced in a continuous and physiological way inside the cells.

The genetic inactivation of GPX1 in mice casues a reduction of 20% in body weight compared to normal animals and increases the level of lipid peroxides in the liver. Moreover, liver mitochondria show an increased release of hydrogen peroxide and decreased mitochondrial respiratory control ratio and power output index. Hence, the genetic inactivation of GPX1 results in growth retardation, presumably due in part to reduced mitochondrial energy production as a product of increased oxidative stress [114].

GPX4 is a monomer able to reduce hydroperoxides in complex lipids, such as those inserted into bio membranes or lipoproteins [116]. There are three different isoforms of the enzyme: cytosolic, ubiquitous, mitochondrial (mGPx4), and sperm nuclear (snGPx4), expressed mainly in testis with only marginal amounts in other tissues [116].

GPx4 is synthesized in two forms, one long (23 kDa) and one short (20 kDa). The long form is localized in the mitochondria because it possesses a mitochondrial signal peptide, while the short GPx4 is localized in other cell organelles [117].
Whole GPx4 knockout mice do not survive, while mGPx4-only knockout mice are fully viable and develop normally, even though male mice are completely sterile [118].

GSSG produced by GPX activity cannot leave the mitochondria [119]. It is recycled back to GSH by the enzyme glutathione reductase (GR), which uses reduced nicotinamide adenine dinucleotide phosphate (NADPH) as a hydrogen donor [120]. GR contains two highly conserved domains: one binds FAD and NADPH, and the other is an interface dimerization domain. It also has two cysteines in the catalytic site, which form a disulfide bond. As expected, glutathione reductase tends to accumulate in cell regions of high electron flux, where reactive species are generated [120]. In eukaryotes it is found in the cytoplasm and within organelles including the nucleus and the mitochondria [121–123]. Glutathione reductase is translocated across the mitochondrial membranes from the cytosol. In human cells, a single gene expresses both the cytosolic and mitochondrial forms of glutathione reductase [124]. The GR destined for different cellular compartments is synthesized using alternative in-frame start codons; if the synthesis starts at the first AUG codon, a long form is obtained, and this isoform is marked for transport to the mitochondria. If translation starts at the second AUG codon, then the protein will remain in the cytosol [124].

The system of the thioredoxin comprises thioredoxin reductase (TrxR), thioredoxin (Trx), and peroxiredoxin (Prx). TrxR passes electrons from NADPH to Trx, whose reduced form donates an electron to Prx that, in turn, reduces hydrogen peroxide to water [125].

TrxRs are high-molecular-weight selenoenzymes [126]. Three iso-forms of TrxRs exist: the cytosolic TrxR1, the mitochondrial TrxR2 and the testicular TrxR3 or thioredoxin glutathione reductase [127]. The mitochondrial TrxR2 contains selenocysteine, is the key regulator of the thioredoxin system, and is essential for the redox homeostasis of the mitochondria [126,128,129].

The Trxs contain a thiol motif of the preserved active site. There are two isoforms, of which Trx1 is found mainly in the cytoplasm and nucleus and Trx2 in the mitochondria [130]. Both Trx2 and mitochondrial GSH/GSSG are redox systems distinct from the Trx1 and GSH/GSSG cytosolic systems [131,132].

Prxs are a large family of thiol-dependent peroxidases which, in the mammalian cell, comprise six isoforms [133]. Prx1, 2 and 6 are found in the cytoplasm, Prx4 in the endoplasmic reticulum, Prx3 in the mitochondria and Prx5 in various compartments, including peroxisomes and mitochondria [134].

The thioredoxin system is the primary defense against the peroxides produced in mitochondria, such as hydrogen peroxide and peroxynitrite [135]. TrxR2 role is to maintain Trx2 in its reduced state by using electrons from NADPH. Trx2 in turn is a cofactor of Prx3 and Prx5. Prx3 and Prx5 reduce H$_2$O$_2$ and peroxynitrite generated by mitochondrial metabolism [126,128,135–138].

In vascular endothelial cells, TrxR2 plays a key role in the control of vascular integrity. Its targeted loss causes disruption of both nitric oxide and redox homeostasis in vivo. When TrxR2 activity is impaired, the steady-state levels of peroxynitrite increase. This increase reflects the decreased bioavailability of NO$^\cdot$ due to its O$_2^•^-$-mediated oxidative inactivation. Thus, TrxR2 regulates peroxynitrite levels by providing reducing equivalents to mitochondrial peroxiredoxins which, in turn, catalytically reduce peroxynitrite to nitrite [139].

Cox and co-workers reported that approximately 90% of the H$_2$O$_2$ produced by mitochondria is metabolized by Prx3, and only a small but significant amount by Prx5 [140]. GPX1 reaction with H$_2$O$_2$ shows a rate constant higher and a lower mitochondrial concentration than Prx3. The low concentration restricts its power to compete directly with Prx3.

The GPX/GR and Trx/TrxR/Prx systems require NADPH as a source of electrons necessary for their activity. Several sources of NADPH exist. The first step of the pentose phosphate pathway, catalyzed by glucose-6-phosphate dehydrogenase (G6PD), was believed to be the primary source of NADPH generation. Other equally important enzymes were described. These enzymes include the NADP+-specific forms of isocitrate dehydro-
genase, malic enzyme, aldehyde dehydrogenase, and NAD kinase [141]. Furthermore, a
direct trans-hydrogenation between NAD and NADP is verified in mitochondria [142].
The pool of NADPH and GSH in mitochondria is sufficient to counteract a sudden increase
in ROS. However, the antioxidant defense system needs a continuous replenishment of NADPH
and GSH, which is dependent on the capacity of the enzymes to restore these molecules.

4.2.2. Low-Molecular-Weight Antioxidants

Mitochondria contain an efficient low-molecular-weight antioxidant system composed
of molecules endogenously made or introduced with food.

Mitochondrial Glutathione

The tripeptide γ-glutamyl-cysteine-glycine (GSH) is the main ubiquitous non-enzymatic
regulator of intracellular redox homeostasis. It synthesizes in the cytosol in a two-step
reaction that requires metabolic energy. In the first reaction, the enzyme γ-glutamylcysteine
synthetase catalyzes the reaction between glutamate and cysteine that leads to the formation
of γ-glutamylcysteine. The first step is rate-limiting due to the generally low availability
of cysteine and is also a regulatory step because GSH inhibits it. The GSH inhibition is
necessary to maintain a proper GSH concentration, intracellularly [143,144]. In the second
step, the enzyme GSH synthetase (GS) catalyzes the reaction between γ-glutamylcysteine
and glycine. Part of the tripeptide synthesized in the cytosol transfers to cellular organelles
such as the endoplasmic reticulum, nucleus, and mitochondria constituting separate redox
pools, distinct from the cytoplasmic ones [145].

GSH can easily pass through the external mitochondrial membrane using porine
channels. However, due to its anionic nature at physiological pH, GSH cannot diffuse
through the inner mitochondrial membrane into the matrix due to the negative membrane
potential of the intermembrane space. Consequently, the GSH of the mitochondrial matrix
derives from the cytosol through a system located in the membrane that transports the
GSH into the mitochondrial matrix against an electrochemical gradient. This agrees with
the observation that the cytoplasmic GSH content decreases in some conditions, but the
mitochondrial GSH content remains constant [146]. Two carriers, the dicarboxylate (DCC)
and the 2-oxoglutarate (OGC), which exchange GS- with other anions so that no charges
transport occurs through the membrane [147], were involved in GSH transport through
the inner mitochondrial membrane in liver and kidney, to date [148,149]. In the liver,
the transport of GSH mediated by OGC decreases in mitochondria from alcohol-fed rats
and in liver mitochondria enriched in cholesterol [150]. These data suggest that OGC
is sensitive to membrane dynamics [150]. However, other putative mitochondrial GSH
carriers are still unknown [151]. Moreover, S-D-lactoylglutathione, an intermediate of the
glyoxalase system, can enter the mitochondria and be hydrolyzed by the mitochondrial
enzyme glyoxalase II to D-lactate and GSH. Thus, S-D-lactoylglutathione can represent an
alternative source of mitochondrial GSH [152].

Mitochondrial GSH (mGSH) is only 10–15% of the cellular GSH but, due to the low
volume of the matrix, its concentration (10 mM) is higher than the cytosolic GSH [146].

The reduction of the mitochondrial oxidized glutathione occurs due to the GR located
in the matrix that uses as a reducing equivalent source the NADPH produced through
NADP+ trans-hydrogenation, which is NADH- and energy-dependent [153]. In the presence
of an electrochemical proton gradient, under physiological conditions, the reaction
is strongly shifted towards NADPH formation, and the reaction rate is enhanced by 5–10
times [154].

Mari reviewed the contribution of mitochondrial GSH to disease progression in
pathologies as diverse as Alzheimer’s disease, alcoholic and non-alcoholic steatohepatitis,
and diabetic nephropathy [151].
Mitochondrial Coenzyme Q

Coenzyme Q or ubiquinone is a lipophilic molecule present in all tissues and cells, mainly located in the inner mitochondrial membrane. It is composed of a redox-active benzoquinone ring conjugated to an isoprenoid chain. The chain length differs among species. In humans, most ubiquinone contains 10 isoprenyl units and is designated CoQ10 [154]. Each cell synthesises its own CoQ. Isoprene units derive from the mevalonate pathway of acetyl CoA and assemble in polyisoprenylpyrophosphate [155]. The precursor of the quinoid head group is p-hydroxybenzoic acid derived from tyrosine or phenylalanine [155]. The head group of p-hydroxybenzoic acid conjugates to polyisoprenylpyrophosphate. Then, it produces the final CoQ molecule through decarboxylation, hydroxylation, and methylation steps [156,157]. The half-life of CoQ in vivo is about 50–125 h, and its breakdown product is a phosphorylated short-chain derivative, which is excreted in the urine [156,158]. How CoQ is mobilized from its site of synthesis on the inner mitochondrial membrane to other action sites remains a longstanding mystery. Recently, two highly conserved but poorly characterized mitochondrial proteins, Ypl109c (Cqd1) and Ylr253w (Cqd2), which affected this process in yeast, were identified [159].

CoQ carries electrons from complex I and II to complex III of the mitochondrial respiratory chain. It also functions as a fat-soluble antioxidant, scavenging reactive oxygen species and is involved in multiple aspects of cellular metabolism [160]. Indeed, the reduced form of coenzyme Q (ubiquinol) also acts as an effective antioxidant in biological membranes, as suggested by the observation that ubiquinol and α-tocopherol lower the lipid peroxidation in mitochondrial suspensions to the same extent [161].

The antioxidant properties of CoQ10 also depend on its capacity in recycling other antioxidants such as vitamin C and vitamin E [162]. CoQ10 deficiency is found in chronic and age-related diseases. For instance, in cardiovascular diseases (CVDs), the reduced bioavailability of CoQ10 is because statins, one of the most common lipid-lowering drugs, inhibits the common pathway shared by CoQ10 endogenous biosynthesis and cholesterol biosynthesis [162].

CoQ also functions as a cofactor for the H⁺ transport by the uncoupling proteins (UCP-1, 2 and 3) [163,164] that dissipate chemiosmotic gradients as heat. The uncoupling, in turn, reduces the reduction levels of electron carriers, lowering ROS production.

Finally, CoQ influences the opening of the permeability transition pore (PTP) a mitochondrial channel whose opening causes the collapse of the mitochondrial membrane potential (ΔΨ) leading to apoptosis. Physiological and biochemical studies showed that the effects of cardio protection and the prevention of the apoptosis of CoQ10 may also be due to the direct inhibition of the opening of the mitochondrial PTP during the reperfusion of ischemic heart [165,166]. Indeed, animals’ treatment with CoQ10 decreases disturbances of heart function and normalizes oxygen metabolism after ischemia reperfusion. This effect is accompanied by a substantial stabilization of the mitochondrial membrane. Moreover, the incubation of mitochondria, isolated from rat heart, with CoQ10 (0.01 µM) substantially prevents calcium- and oxidant-induced mitochondrial swelling [165].

Furthermore, CoQ10 treatment reduces apoptosis induced by apoptotic stimuli. This reduction is accompanied by the inhibition of mitochondrial depolarization, the release of cytochrome c and the activation of caspase 9, events caused by the opening of the mitochondrial PTP suggesting that the antiapoptotic activity of CoQ10 could be related to its ability to prevent this phenomenon [166].

4.2.3. Diet-Derived Mitochondrial Antioxidants

The mitochondrial antioxidant defenses also comprise molecules deriving from the diet. Such substances can reach and accumulate in mitochondria.

Vitamin C (Vit C) is a water-soluble vitamin. It is also named ascorbic acid (AA) or ascorbate. Vit C is produced in plant cells but synthesized endogenously in animal species, except for humans, monkeys, bats, guinea pigs, and some reptiles [167]. Humans lost this capability because of a series of inactivating mutations of the gene encoding
gulonolactone oxidase, a key enzyme for the biosynthesis of Vit C [168]. Animals for which ascorbic acid is a vitamin acquire it from food sources via a substrate-saturable transport mechanism. The oral Vit C intake determines plasma concentrations that are tightly regulated. With Vit C oral intake exceeding 200 mg daily, the plasma vitamin C concentration does not increase further through increasing the oral intake [169]. The maximal plasma concentration induced by the oral intake of Vit C is about 200 µM. In healthy humans, the physiological plasma concentrations of the vitamin ranges from 40 to 100 µM [169,170]. Although the plasma level of vitamin C is in the micromolar range under physiological conditions and with the typical dietary intake, the intracellular level of the vitamin is in the millimolar range. This high concentration is due to the selective intracellular accumulation through a transport system of vitamin C present in the plasma membrane [171].

Vit C concentration in mammalian mitochondria increases in dietary vitamin C supplementation [172–174]. This increase depends on the presence of specialized mitochondrial mechanisms of uptake. The carrier of the oxidized form of the vitamin, dehydroascorbic acid (DHA), was initially identified as the facilitative glucose transporter 1 (GLUT1) [175]. Moreover, GLUT10, another glucose transporter, which is expressed highly in the mitochondria of smooth muscle cells and insulin-stimulated adipocytes facilitates the transport of DHA. DHA can protect against oxidative stress. This protection is compromised when GLUT10 expression in mitochondria is inhibited [176].

In a subsequent study, a mitochondrial ascorbic acid transporter (MAT) from both rat liver and potato mitochondria was reconstituted in proteoliposomes, showing that this was not a GLUT since it showed different biochemical features [177]. The protein has a molecular mass in the range of 28–35 kDa, and catalyzes the saturable, temperature, pH-dependent, unidirectional transport of both ascorbic acid (AA) and DHA. The transport activity is sodium-independent, and it is optimal at acidic pH values. It is stimulated by the proton gradient, thus supporting the idea that ascorbate is symported with H⁺ [177].

The dehydroascorbic acid (DHA) that enters into the mitochondria is reduced and accumulated as mitochondrial AA (mtAA). Mitochondrial ascorbate can deactivate ROS, and thus protect both the mitochondrial genome and membranes from oxidative damage [175]. Ascorbate is recycled in mitochondria by various mechanisms, including the reduction by α-lipoic acid and/or thioredoxin reductase, or a GSH-dependent reduction. The latter is one of the main mechanisms of ascorbate recycling [178].

Vitamin E is the main lipid-soluble antioxidant in the cells. It comprises tocopherols and tocotrienols that contain a chromanol ring with a 13-carbon chain at the C2 position. Vitamin E synthesizes in plants as four homologues differing for the number and localization of methyl groups attached to the chromanol ring (named α, β, γ, and δ). Tocopherols have a saturated side chain and three chiral carbons, resulting in eight stereoisomers. Tocotrienols have an unsaturated side chain with three double bonds and one chiral carbon forming two stereoisomers [179,180].

Vitamin E absorbed in the intestine enters the circulation through the lymphatic system. It is packaged together with the lipids in chylomicrons. At this stage, there are no differences in the plasma levels of the different forms of vitamin E. It enters the hepatocytes by endocytosis of the remnants of chylomicron and reaches the late endosomal compartment. Preferentially, the α-tocopherol (α-T) binds to an α-tocopherol transfer protein (αTTP), that localizes on the outer leaflet of the endosomal membrane. The bond between vitamin E and αTTP favors the transfer of α-tocopherol to the plasma membrane. Here, the binding to the resident phosphatidylinositol 4,5-bisphosphate determines a conformational change, resulting in the release of α-T and its incorporation into the membrane [181–183]. Subsequently, vitamin E bonds with the ATP-binding cassette transporter 1 (ABCA1) that allows vitamin E to exit the cells, be inserted into lipoproteins, and delivered to extrahepatic tissues [181]. α-TTP has a large affinity for α-tocopherol (100%) and a much lower affinity for β-, γ- and δ-tocopherol (50%, 10–30%, or 1%, respectively) [184]. A large portion of non-α-T forms of vitamin E is oxidized to quinones or conjugated with glucuronic acid
and excreted in the feces [185]. The hydrolysis of VLDL by lipoprotein lipase delivers α-tocopherol to extrahepatic tissues and yields low-density lipoproteins (LDLs). LDLs, which carry the major portion of plasma α-tocopherol, provide a further route for the delivery of α-tocopherol to extrahepatic tissues via the LDL receptor-mediated uptake pathway [186]. Vitamin E also localizes in the membrane of organelles, such as the endoplasmic reticulum, mitochondria, and peroxisomes [187–191].

The supplementation with vitamin E increases its content in mitochondria from the liver, skeletal and cardiac muscle [192–194]. It was proposed that vitamin E reaches the mitochondrial membrane through passive diffusion, which seems to be the main driving force for the distribution of vitamin E within the cell [195]. Vitamin E exerts antioxidant effects in different ways. It can deactivate oxygen singlet (\(1{O_2}\)) by quenching, and one molecule of α-tocopherol can deactivate up to 120 \(1{O_2}\) before its degradation [196]. Vitamin E is a potent, chain-breaking antioxidant that chemically scavenges \(1{O_2}\) and lipid peroxyl radicals. In the first case, it irreversibly produces quinones and epoxides. In the second case, it converts in the tocopheroxyl radical [197], which can be recycled back to α-tocopherol by ascorbate. In this way, tocopherols trap propagating radical intermediates produced during lipid peroxidation and break the chain reactions of radicals.

The protective effects of vitamin E from oxidative damage also depend on its capacity to scavenge superoxide radicals, thus downregulating mitochondrial ROS production [198]. The α-tocopheryl radical produced in such a reaction seems to be repaired by a superoxide radical [199]. Following α-tocopherol-administration, the \(O_2^-\) release rate of mouse submitochondrial particles from the liver and skeletal muscle is inversely related to the α-tocopherol content [200]. The rate of \(H_2O_2\) released by mitochondria isolated from liver and skeletal muscle is reduced following vitamin E supplementation in a dose-dependent manner [201]. Moreover, in intact mitochondria, the reduction in the \(H_2O_2\) release rate is associated with the lowering in both indexes of oxidative damage to lipids and proteins and the susceptibility to in vitro oxidative stress [192]. In membranes, a ratio of one tocopherol per thousand of polyunsaturated fatty acid side chains is normal; therefore, the vitamin E protective effects are obtained with a low vitamin membrane concentration [202]. The mitochondrial antioxidant power may also depend on other fat-soluble antioxidants that can localize in the mitochondria these include astaxanthin, a red pigment that belongs to the subclass of xanthophylls, which are able to counteract mitochondrial dysfunction as they are able to permeate and co-localize in the mitochondria [203]. It was shown that astaxanthin prevents mitochondrial dysfunction due to oxidative stress and mitigates oxidative stress in various pathological conditions [203].

4.2.4. Mitochondrial Systems of Repair

The accumulation of oxidatively damaged macromolecules in mitochondria is prevented by an efficient system deputed to their repair.

Lipids of the mitochondrial membranes are continuously exposed to ROS and are highly susceptible to oxidative damage.

Most mitochondrial lipids are synthesized in the endoplasmic reticulum (ER) and transported to the mitochondria, but cardiolipin and phosphatidylethanolamine are synthesized within the inner membrane of the mitochondria and are critical for maintaining the architecture of the mitochondrial cristae [204].

The glycerophospholipid of the inner mitochondrial membrane, cardiolipin, acts as an anchor for respiratory supercomplexes and mitochondrial DNA during replication. Cardiolipin is essential for mitochondrial health [205]; its oxidation is reported as a primary event in the release of cytochrome c and the increase in the permeability of the mitochondrial membrane to apoptosis factors [206]. Moreover, when lipid oxidation is associated with iron overload, ferroptosis takes place, which is a form of iron-dependent cell death [207]. Cardiolipin peroxidation and peroxidated lipid degradation products reduce the activities of the respiratory chain complexes. Moreover, they promote the opening of the mitochondrial transition pore and mitochondrial permeability transition [208]. GPX4
is the key enzyme involved in the protection of mitochondrial lipids from the effects of peroxidation. Its overexpression counteracts the lowering of the inner membrane potential and ATP production in conditions that lead to oxidative stress [208]. More recently, another mechanism that can contribute to containing mitochondrial lipid oxidation was suggested. This mechanism involves the ubiquinol-mediated repair of mitochondrial peroxidized lipids [209]. The enzyme, dihydroorotate dehydrogenase, catalyzes the conversion of dihydroorotate to orotate in a reaction of oxidation, in which ubiquinone is converted into ubiquinol. Therefore, indirectly, dihydroorotate dehydrogenase can protect cells from lipid peroxidation by generating ubiquinol, which acts in the repair of oxidative damage to mitochondrial lipids [209].

Oxidatively modified proteins can accumulate in mitochondria at high levels both in basal and stress conditions. The proteins are oxidatively modified in an irreversible way, i.e., proteins containing carbonyl groups must be eliminated to prevent the genesis of insoluble aggregates, which can be dangerous for the mitochondria. There are a number of mitochondrial systems that can identify and remove oxidatively damaged polypeptides.

Twenty or more proteases constitute the mitochondrial proteolytic system, which is involved in several functions [210]. The control of the quality of the mitochondrial proteins is the main function of the mitochondrial proteolytic system that allows the extension of the half-life of mitochondria. Some proteases, localized both in the intermembrane space and in the matrix, play different roles. They regulate the ratios of subunits of mitochondrial complexes that are encoded by nuclear and mitochondrial DNA; eliminate damaged, unfolded, or misfolded proteins; and control the protein turnover [211].

Two complexes of proteases act in the quality control of protein across the inner mitochondrial membrane, called membrane-bound AAA complexes (ATPases associated with a wide variety of cellular activities) [212]. These membrane-embedded peptidases are named m- and i-AAA proteases for their different topologies in the inner membrane; the m-AAA protease is active in the matrix and the i-AAA protease on the intermembrane side of the membrane [212]. Other peptidases contribute to the quality control of the inner membrane, one of which is the metallopeptidase OMA1 [213]. An ATP serine protease, Lon protease, degrades denatured or oxidatively damaged proteins in the matrix [214,215], avoiding oxidized proteins that accumulate in the mitochondria of all human tissues, particularly in the heart, brain, liver, and skeletal muscles. The age-dependent decline in the activity and regulation of this proteolytic system may underlie the accumulation of oxidatively modified and dysfunctional proteins and loss in mitochondrial viability [216].

Several kinds of chemical modifications can damage DNA. These modifications include the spontaneous deamination and base loss, non-enzymatic alkylation and enzymatic methylation, adducts formation with aromatic molecules, intra- and inter-strand cross-links, protein–DNA adduct formation, and oxidation [217,218].

Mitochondria possess their own DNA genome (mtDNA) that encodes only for 13 polypeptides, which are essential components of four of the five complexes of the respiratory chain. Each mitochondrion contains between 2 and 10 molecules of DNA, which are organized as nucleoids [219]. ROS can produce a variety of DNA damages such as oxidized DNA bases, abasic sites, and double-strand breaks (DSBs). The damages in the mitochondrial DNA can have harmful effects, including mitochondrial diseases, aging and age-related diseases. The replication of damaged mtDNA can lead to cellular damage. Therefore, mitochondria adapted mechanisms to repair damaged DNA. These mechanisms rely on nuclear-encoded DNA repair proteins that are translocated into the mitochondria [220]. The repair of mtDNA damage relies on Base Excision Repair (BER), Homologous Recombination (HR) and Microhomology-mediated End Joining (MMEJ). These repair mechanisms do not operate in isolation, and evidence for the interplay between pathways exist [221].

BER is initiated by a DNA glycosylase that recognizes and cleaves the glycosidic bond between damaged nitrogenous bases and the pentose moiety. Then, the site is cleaved by endonuclease lyase in order to cleave the DNA backbone. Following the DNA polymerase
and DNA ligase, the repair is completed. Mitochondrial BER enzymes are encoded by the nuclear DNA, mostly existing as splice variants or as proteins with post-translational modifications [222].

While nuclear BER decreases with age, the mitochondrial BER may increase with age. This increase is not sufficient to prevent the gradual accumulation of lesions in the mitochondrial DNA with age.

HR and MMEJ play a central role in the double-strand breaks (DSBs) repair in mitochondria [223,224].

5. The Nuclear Factor Erythroid 2–Related Factor 2 (Nrf2) and Mitochondrial Antioxidants

Nuclear factor erythroid 2–related factor 2 (Nrf2) regulates cytoprotective responses to stress induced by electrophilic compounds and ROS [225].

In cells not exposed to a stress condition, the Nrf2 protein levels are low because proteasomes degrade it after ubiquitination. The Kelch-like, ECH-associated protein 1 (Keap1) is the main negative regulator of Nrf2 and mediates the ubiquitination and degradation of Nrf2 [226,227]. In conditions of stress, or the presence of Nrf2-activating compounds, the cysteine residues of Keap1 oxidize and Keap1 loses its ubiquitin ligase activity. This modification allows for the release of Nrf2 that is phosphorylated and moves into the nucleus. Here, Nrf2 binds to small proteins of musculoaponeurotic fibrosarcoma (Maf) and forms heterodimers that bind to the antioxidant response element (ARE) in the promoter regions of Nrf2-regulated genes [228,229].

Another model of the Nrf2-Keap1 pathway proposes that Nrf2 is primarily a nuclear protein and that it is expressed and constitutively recruited into chromatin to drive basal gene expression. Keap1 appears to repress Nrf2 activity by transiently moving into the nucleus to promote its ubiquitination. The steady-state level of Nrf2 is maintained by a dynamic pathway that balances its constitutive expression with a degradation process regulated by Keap1 downstream of its role as a transcriptional activator [230]. Under stressful conditions, Keap1 does not pass into the nucleus where Nrf2 accumulates and increases transcription. This model explains how Nrf2 exerts its dual function of controlling gene expression in a constitutive and inducible way.

Whatever the gene regulation pathway operated by Nrf2, this certainly is the main factor regulating antioxidant defenses. Indeed, it regulates more than 200 cytoprotective genes in response to oxidative stress [231].

Nrf2 activation induces mitochondrial antioxidant enzymes such as thioredoxin reductase-2 (TrxR2), peroxiredoxin 3 (Prx3) and 5 (Prx5), and SOD2 [232].

In some circumstances, the activation of mitochondrial antioxidant gene expression by Nrf2 requires other partners to verify or is secondary to the Nrf2-induced expression of other nuclear factors. In mice with Staphylococcus aureus-induced peritonitis, the co-activator peroxisome proliferator-activated receptor-gamma 1α (PGC-1α) acts as a co-activator for Nrf2 during Sod2 induction [233]. In this condition, PGC-1α plays a key role in regulating hepatic mitochondrial biogenesis and in protecting against mitochondrial oxidative stress.

Moreover, in vitro studies using trabecular meshwork cells demonstrated that the quercetin induction of Prx3 and Prx5 expression was verified through the Nrf2 induction of nuclear respiratory factor 1 (NRF-1) [234].

Nrf2 can also affect mitochondrial characteristics. Nrf2 induces mitochondrial biogenesis; mitophagy increases mitochondrial antioxidant capacity and activates oxidative phosphorylation regulating substrate availability [232,235–237].

Nrf2 regulates some key metabolic genes or crosstalk with other transcription factors. Nrf2 activation enhances glycolytic flux, pentose phosphate pathway, amino acid metabolism, and glutaminolysis. These Nrf2-induced activations determine an increased flux of substrates and reduce equivalents into the Krebs’s cycle and the mitochondrial respiratory chain. The genetic activation of Nrf2 in cells increases the oxygen consumption rates, mitochondrial membrane potential (ΔΨm), ATP levels (Holmstrom et al., 2013) and
fatty acid oxidation [238]. Nrf2 upregulates the uncoupling protein 3 (UCP3), which is associated with decreased superoxide formation [239]. Nrf2 activation can also protect mitochondrial DNA (mtDNA), as shown in intestinal epithelial cells subjected to ischemia reperfusion-induced damage [240].

Experimental evidence suggests that Nrf2, in addition to antioxidant responses, is involved in many other cellular processes, including metabolism and inflammation, and its functions are beyond those originally envisioned [241].

Nrf2 involvement in mitochondrial biogenesis is verified through the activation of NRF-1, which induces the transcription of the mitochondrial transcription factor A (TFAM) [242]. NRF-1 activates the transcription of several mitochondrial genes, in particular genes encoding the subunits of the mitochondrial respiratory chain complexes and the transcription of TFAM, which regulate the replication and transcription of the mitochondrial genome [243].

Murata et al. [244] showed that Nrf2 regulates the expression of the PTEN-induced putative kinase 1 (PINK1), an essential factor for controlling mitochondrial quality and protecting cells from oxidative stresses. Damaged mitochondria arising from stress conditions induce the Nrf2-dependent transcription of the PINK1 gene through the production of ROS. PINK1 accumulates on the outer membrane of depolarized mitochondria. Accumulated PINK1 recruits Parkin, a ubiquitin ligase, and Parkin can mediate the autophagic elimination of depolarized mitochondria [245]. PINK1 is necessary for mitochondrial quality control and contributes to mitophagy [246,247].

Some data indicate that mitochondrial ROS (mtROS) can activate Nrf2 in some conditions and deactivate it in others. Therefore, it was suggested that a high level of mtROS inactivates the signalling cascade that activates Nrf2, thus leading to the inhibition of Nrf2 activity [248]. Furthermore, a role in Nrf2 inhibition can also be played by ROS that are produced in the matrix or intermembrane space or even by the type of ROS produced. Further studies are needed to clarify these aspects [248].

6. Mitochondria Can Remove ROS Produced by Other Cellular Sources

The mitochondrial antioxidant system seems to remove not only the ROS produced by mitochondria, but also the $\text{O}_2^{\bullet-}$ and $\text{H}_2\text{O}_2$ produced in the surrounding medium [5].

The ability of mitochondria to remove $\text{H}_2\text{O}_2$ depends on respiration and is different in the mitochondria of different tissues. Moreover, it changes depending on the metabolic state and the respiratory substrate. Zoccarato et al., showed that brain mitochondria remove exogenous $\text{H}_2\text{O}_2$ faster with malate and glutamate than with succinate as substrates of the respiration [249]. Moreover, they found that $\text{H}_2\text{O}_2$ removal in the State 3 of respiration was slightly lower than in State 4. The $\text{H}_2\text{O}_2$ removal supported by succinate is nearly the same in State 4 and in State 3 of respiration. They suggested that the $\text{H}_2\text{O}_2$-removing capacity of respiring mitochondria depends primarily on the activities of GPX and GR, and that other antioxidant systems only contribute ~20% of detoxifying activity [249].

Later, this idea was questioned by Dreshel and Patel, who found that the glutathione system makes only a minimal contribution to the brain’s mitochondrial removal capacity. Using pharmacological inhibition of mitochondrial antioxidant enzymes, they found that the rate of $\text{H}_2\text{O}_2$ removal only decreased by 25% after GR inhibition, and GPX inhibition had no effect [250]. Conversely, the inhibition of TrxR caused a reduction in the $\text{H}_2\text{O}_2$ removal rates by 80%, and the oxidation of peroxiredoxin lowered this rate by 50%. Non-enzymatic mitochondrial processes also contributed to the removal of hydrogen peroxide but to a lesser extent (estimated to be about 10%) [250].

Other studies showed that also liver mitochondria removed $\text{H}_2\text{O}_2$ and that such removal was verified at higher rates in the presence of respiratory substrates. However, the $\text{H}_2\text{O}_2$ removal rates are similar with succinate or pyruvate/malate, substrates linked to complex II and I, respectively [251] (Venditti et al., 2014). The selective pharmacological inhibition of antioxidant enzymes shows that catalase is the major contributor to $\text{H}_2\text{O}_2$ removal (~31%) and that TrxR and GPX also contribute significantly, but to a lesser extent
(≈20% and 23%, respectively) [252]. The contribution of non-enzymatic processes to H₂O₂ removal is about 27% and appears to depend mainly on haemoproteins, as suggested by its changes in the mitochondria of animals with different cytochrome c content [252]. Indeed, it was shown that, in hypothyroid and hyperthyroid conditions, the H₂O₂ removal rate from liver mitochondria is lower and higher, respectively, compared to the euthyroid ones. These changes were associated with similar changes in cytochrome c content and in the contribution of non-enzymatic systems to peroxide removal [252].

During state 4 of respiration, the mitochondria of the heart and liver remove H₂O₂ at similar rates [253]. In cardiac mitochondria, enzymatic antioxidant systems contribute to the removal of H₂O₂ to the same extent as hepatic mitochondria, but, unlike the liver, the non-enzymatic system contributes to a greater extent (≈36.8%). This effect is consistent with the higher content of hemoproteins [253].

7. Mitochondrial ROS Removal and ROS Signaling

So far, it is established that ROS can regulate various cell signaling pathways and numerous physiological processes [254]. This suggests that maintaining the adequate cellular levels of H₂O₂ is of prime importance for cell function and survival.

The different characteristics of mitochondria render them capable of controlling the cytosolic level of H₂O₂ [255]. First, mitochondria can maintain high levels of NADPH in the matrix, which is necessary for the activities of most of the H₂O₂-metabolizing enzymes. To the maintaining of such high level a main contribution is due to the respiration-dependent transhydrogenase. Secondly, the resistance of the Prx3 and 5 located in the matrix to oxidative inactivation, unlike cytosolic Prx1, makes the mitochondria capable of removing H₂O₂ even if H₂O₂ levels are high. Third, mitochondria possess high amounts of mitochondrial GSH and antioxidant enzymes. For these reasons, it was hypothesized that mitochondria possess several redox mechanisms that allow them to potentially play an important role in the modulation of H₂O₂-activated signals in the cytosol, facilitating their desensitization [247].

8. Conclusions

Until recently, mitochondria were regarded only for their role as producers of aerobic energy in eukaryotic cells. Indeed, they are the sites of oxidative phosphorylation, the process by which the transfer of electrons from energy substrates to oxygen is coupled with the synthesis of ATP. Later, the observation that the flow of electrons in the respiratory chain also determines the genesis of ROS capable of causing damage to cellular components gave rise to the idea that mitochondria are involved in the degenerative phenomena that cause various diseases and ageing.

Subsequently, another role emerged for the mitochondria, as a system capable of protecting the cell from oxidative damage. Indeed, several data suggest that the mitochondrial systems evolved to protect mitochondria from the ROS they produce can also eliminate ROS produced by other cellular sources. It can be hypothesized that this action, which is particularly important in physio-pathological conditions, in which the cellular production of ROS occurs to a greater extent, is more effective in tissues that have an abundant mitochondrial population. Moreover, several experimental evidence, suggested that mitochondria can control the cellular H₂O₂ levels which make them regulators of the ROS-mediated signaling pathways.

**Author Contributions:** Conceptualization, G.N., G.F. and P.V.; writing—original draft preparation, P.V.; writing—review and editing, P.V., G.N. and G.F. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Conflicts of Interest:** The authors declare no conflict of interest.
References

1. Andreyev, Y.; Kushnareva, Y.E.; Starkov, A.A. Mitochondrial metabolism of reactive oxygen species. Biochemistry 2005, 70, 200–214. [CrossRef] [PubMed]
2. Murphy, M.P. Mitochondrial thiols in antioxidant protection and redox signaling: Distinct roles for glutathionylation and other thiol modifications. Antioxid. Redox Signal. 2012, 16, 476–495. [CrossRef] [PubMed]
3. Valko, M.; Rhodes, C.; Moncol, J.; Izakovic, M.; Mazur, M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem. Biol. Interact. 2006, 160, 1–40. [CrossRef] [PubMed]
4. Brand, M.D.; Affourtit, C.; Esteves, T.C.; Green, K.; Lambert, A.J.; Miwa, S.; Pakay, J.L.; Parker, N. Mitochondrial superoxide: Production, biological effects, and activation of uncoupling proteins. Free Radic. Biol. Med. 2004, 37, 755–767. [CrossRef] [PubMed]
5. Venditti, P.; Di Stefano, L.; Di Meo, S. Mitochondrial metabolism of reactive oxygen species. Mitochondrion 2013, 13, 71–82. [CrossRef] [PubMed]
6. Hinchcliffe, P.; Sanzanov, L.A. Organization of iron–sulfur clusters in respiratory complex I. Science 2005, 309, 771–774. [CrossRef]
7. Friedrich, T.; Bottcher, B. The structure of the respiratory complex I: A Lego System. Biochim. Biophys. Acta 2004, 1608, 1–9. [CrossRef]
8. Cecchini, G. Function and structure of complex II of the respiratory chain. Annu. Rev. Biochem. 2003, 72, 77–109. [CrossRef] [PubMed]
9. Hatefi, Y. The mitochondrial electron transport and oxidative phosphorylation system. Annu. Rev. Biochem. 1985, 54, 1015–1069. [CrossRef]
10. Tsukihara, T.; Aoyama, H.; Yamashita, E.; Tomizaki, T.; Yamaguchi, H.; Shinzawa-Itoh, K.; Nakashima, R.; Yaono, R.; Yoshikawa, S.; Tsukihara, T. Structures of metal sites of oxidized bovine heart cytochrome c oxidase at 2.8 A. Science 1995, 269, 1069–1074. [CrossRef]
11. Schägger, H.; Pfeiffer, K. Supercomplexes in the respiratory chains of yeast and mammalian mitochondria. EMBO J. 2000, 19, 1777–1783. [CrossRef]
12. Genova, M.L.; Lenaz, G. Functional role of mitochondrial respiratory supercomplexes. Biochim. Biophys. Acta 2014, 1837, 427–443. [CrossRef]
13. Schägger, H.; de Coo, R.; Bauer, M.F.; Hofmann, S.; Godinot, C.; Brandt, U. Significance of respirasomes for the assembly/stability of human respiratory chain complex I. J. Biol. Chem. 2004, 279, 36349–36353. [CrossRef]
14. Maranzana, E.; Barbero, G.; Falasca, A.I.; Lenaz, G.; Genova, M.L. Mitochondrial respiratory supercomplex association limits production of reactive oxygen species from complex I. Antioxid. Redox Signal 2013, 19, 1469–1480. [CrossRef]
15. Shimada, S.; Shinzawa-Itoh, K.; Baba, J.; Aoe, S.; Shimada, A.; Yamashita, E.; Kang, J.; Tateno, M.; Yoshikawa, S.; Tsukihara, T. Complex structure of cytochrome c-cytochrome c oxidase reveals a novel protein-protein interaction mode. EMBO J. 2017, 36, 291–300. [CrossRef]
16. Mitchell, P.; Moyle, J. Stoichiometry of proton translocation through the respiratory chain and adenosine triphosphatase systems of rat liver mitochondria. Nature 1965, 208, 147–151. [CrossRef]
17. Walker, J.E.; Collinson, I.R.; Van Raaij, M.J.; Runswick, M.J. Structural analysis of ATP synthase from bovine heart mitochondria. Methods Enzymol. 1995, 260, 163–190. [CrossRef]
18. Klingenberg, M. The ADP and ATP transport in mitochondria and its carrier. Biochim. Biophys. Acta 2008, 1778, 1978–2021. [CrossRef]
19. Acín-Perez, R.; Bayona-Baluyó, M.P.; Bueno, M.; Machicado, C.; Fernandez-Silva, P.; Perez-Martos, A.; Montoya, J.; Lopez-Perez, M.J.; Sancho, J.; Enriquez, J.A. An intragenic suppressor in the cytochrome c oxidase I gene of mouse mitochondrial DNA. Hum. Mol. Genet. 2003, 12, 329–339. [CrossRef]
20. Dalmonte, M.E.; Forte, E.; Genova, M.L.; Giuffre, A.; Sarti, P.; Lenaz, G. Control of respiration by cytochrome c oxidase in intact cells: Role of the membrane potential. J. Biol. Chem. 2009, 284, 32331–32335. [CrossRef] [PubMed]
21. Kalpace, H.A.; Wan, J.; Morse, P.T.; Zurek, M.P.; Turner, A.A.; Khobeir, A.; Yazdi, N.; Hakim, L.; Liu, J.; Vaishnav, A.; et al. Cytochrome c phosphorylation: Control of mitochondrial electron transport chain flux and apoptosis. Int. J. Biochem. Cell Biol. 2020, 121, 105704. [CrossRef] [PubMed]
22. Kadenbach, B. Regulation of cytochrome c oxidase contributes to health and optimal life. World J. Biol. Chem. 2020, 11, 52–61. [CrossRef] [PubMed]
23. Clementi, E.; Brown, G.C.; Foxwell, N.; Moncada, S. On the mechanism by which vascular endothelial cells regulate their oxygen consumption. Proc. Natl. Acad. Sci. USA 1999, 96, 1559–1562. [CrossRef]
24. Brown, G.C. Regulation of mitochondrial respiration by nitric oxide inhibition of cytochrome c oxidase. Biochim. Biophys. Acta 2001, 1504, 46–57. [CrossRef]
25. Taylor, C.T.; Moncada, S. Nitric oxide, cytochrome C oxidase, and the cellular response to hypoxia. Arterioscler. Thromb. Vasc. Biol. 2010, 30, 643–647. [CrossRef]
26. Antunes, F.; Boveris, A.; Cadenas, E. On the mechanism and biology of cytochrome oxidase inhibition by nitric oxide. Proc. Natl. Acad. Sci. USA 2004, 101, 16774–16779. [CrossRef]
27. Giulivi, C.; Kato, K.; Cooper, C.E. Nitric oxide regulation of mitochondrial oxygen consumption I: Cellular physiology. Am. J. Physiol. Cell. Physiol. 2006, 291, C1225–C1231. [CrossRef]
28. Chance, B.; Williams, G.R. The respiratory chain and oxidative phosphorylation. Adv. Enzymol. Relat. Subj. Biochem. 1956, 17, 65–134.
29. Arnold, S.; Kadenbach, B. The intramitochondrial ATP/ADP-ratio controls cytochrome c oxidase activity allosterically. FEBS Lett. 1999, 443, 105–108. [CrossRef]

30. Ferguson-Miller, S.; Braunig, D.L.; Margoliash, E. Correlation of the kinetics of electron transfer activity of various eukaryotic cytochromes c with binding to mitochondrial cytochrome c oxidase. J. Biol. Chem. 1976, 251, 1104–1115. [CrossRef]

31. Tuominen, E.K.; Zhu, K.; Wallace, C.J.; Clark-Lewis, I.; Craig, D.B.; Ryttomaa, M.; Kinnunen, P.K. ATP induces a conformational change in lipid-bound cytochrome c. J. Biol. Chem. 2001, 276, 19356–19362. [CrossRef]

32. Lee, I.; Salomon, A.R.; Yu, K.; Doan, J.W.; Grossman, L.I.; Hüttemann, M. New prospects for an old enzyme: Mammalian cytochrome c is tyrosine-phosphorylated in vivo. Biochemistry 2006, 45, 9121–9128. [CrossRef] [PubMed]

33. Yu, H.; Lee, I.; Salomon, A.R.; Yu, K.; Hüttemann, M. Mammalian liver cytochrome c is tyrosine-48 phosphorylated in vivo, inhibiting mitochondrial respiration. Biochim. Biophys. Acta 2008, 1777, 1066–1071. [CrossRef] [PubMed]

34. Mahapatra, G.; Varughese, A.; Ji, Q.; Lee, I.; Li, Q.; Sinkler, C.; Kapralov, A.A.; Moraes, C.T.; Sanderson, T.H.; et al. Phosphorylation of Cytochrome c Threonine 28 Regulates Electron Transport Chain Activity in Kidney: Implications for AMP kinase. J. Biol. Chem. 2017, 292, 64–79. [CrossRef] [PubMed]

35. Wan, J.; Kalpage, H.A.; Vaishnava, A.; Liu, J.; Lee, I.; Mahapatra, G.; Turner, A.A.; Zurek, M.P.; Ji, Q.; Moraes, C.T.; et al. Regulation of Respiration and Apoptosis by Cytochrome c Threonine 58 Phosphorylation. Sci. Rep. 2019, 9, 15815. [CrossRef]

36. Kalpage, H.A.; Vaishnava, A.; Liu, J.; Varughes, A.; Wan, J.; Turner, A.A.; Ji, Q.; Zurek, M.P.; Kapralov, A.A.; Kagan, V.E.; et al. Serine-47 phosphorylation of cytochrome c in the mammalian brain regulates cytochrome c oxidase and caspase-3 activity. FASEB J. 2019, 33, 13503–13514. [CrossRef]

37. Sanderson, T.H.; Mahapatra, G.; Pecina, P.; Ji, Q.; Yu, K.; Sinkler, C.; Varughese, A.; Kumar, R.; Bukowski, M.J.; Tousignant, R.N.; et al. Cytochrome C is tyrosine 97 phosphorylated by neuroprotective insulin treatment. PLoS ONE 2013, 8, e78627. [CrossRef]

38. Schmidt, T.R.; Wildman, D.E.; Opazo, J.C.; Goodman, M.; Grossman, L.I. Rapid electrostatic evolution at the binding site for cytochrome c on cytochrome c oxidase in anthropoid primates. Proc. Natl. Acad. Sci. USA 2005, 102, 6379–6384. [CrossRef]

39. Jensen, P.K. Antimycin-insensitive oxidation of succinate and reduced nicotinamide-adenine dinucleotide in electrontransport particles. I. pH dependency and hydrogen peroxide formation. Biochim. Biophys. Acta 1966, 122, 157–166. [CrossRef]

40. Weisger, R.A.; Fridovich, I. Superoxide dismutase. Organelle specificity. J. Biol. Chem. 1973, 248, 3582–3592. [CrossRef]

41. Loschen, G.; Azzi, A.; Richter, C.; Flohé, L. Superoxide radicals as precursors of mitochondrial hydrogen peroxide. FEBS Lett. 1974, 42, 68–72. [CrossRef]

42. Takeshige, K.; Minakami, S. NADH- and NADPH-dependent formation of superoxide anion by bovine heart submitochondrial particle and NADH-ubiquinone reductase preparation. Biochem. J. 1979, 180, 129–135. [CrossRef]

43. Turrens, J.F.; Boveris, A. Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria. FEBS Lett. 1980, 100, 1430–1436. [CrossRef]

44. Loschen, G.; Flohé, L.; Chance, B. Respiratory chain linked H2O2 production in pigeon heart mitochondria. FEBS Lett. 1971, 18, 261–264. [CrossRef]

45. Paranagama, M.P.; Sakamotop, K.; Amino, H.; Awano, M.; Myoshi, J.H.; Kita, K. Contribution of the FAD and quinine binding sites to the production of reactive oxygen species from Ascaris suum mitochondrial complex II. Mitochondrion 2010, 10, 158–165. [CrossRef]

46. Tretter, L.; Adam-Virzi, V. Generation of reactive oxygen species in the reaction catalyzed by α-ketoglutarate dehydrogenase. J. Neurosci. 2004, 24, 7771–7778. [CrossRef]

47. Starkov, A.A.; Fiskum, G.; Chinnopoulou, C.; Lorenzo, B.J.; Browne, S.E.; Patel, M.S.; Beal, M.F. Mitochondrial α-ketoglutarate dehydrogenase complex generates reactive oxygen species. J. Neurosci. 2004, 24, 7779–7788. [CrossRef] [PubMed]

48. Brand, M.D. Mitochondrial generation of superoxide and hydrogen peroxide as the source of mitochondrial redox signaling. Free Radic. Biol. Med. 2016, 91, 100–115. [CrossRef]

49. Quinlan, C.L.; Orr, A.L.; Perevoshchikova, I.V.; Treberg, J.R.; Ackrell, B.A.; Brand, M.D. Mitochondrial complex II can generate reactive oxygen species at high rates in both the forward and reverse reactions. J. Biol. Chem. 2012, 287, 27255–27264. [CrossRef]

50. Turrens, J.F.; Boveris, A. Generation of superoxide and hydrogen peroxide as the source of mitochondrial respiration. FEBS Lett. 1971, 18, 261–264. [CrossRef]

51. Goncalves, R.L.; Bunik, V.I.; Brand, M.D. Mitochondrial oxidative function: Inhibition of mitochondrial respiration. FEBS Lett. 1979, 100, 1430–1436. [CrossRef]

52. Quinlan, C.L.; Goncalves, R.L.; Hey-Mogensen, M.; Yadava, N.; Bunik, V.I.; Brand, M.D. The 2-oxoacid dehydrogenase complexes in mitochondria can produce superoxide/hydrogen peroxide at much higher rates than complex I. J. Biol. Chem. 2014, 289, 8312–8325. [CrossRef]

53. Han, D.; Canali, R.; Rettori, D.; Kaplowitz, N. Effect of glutathione depletion on sites and topology of superoxide and hydrogen peroxide production in mitochondria. Mol. Pharmacol. 2003, 64, 1136–1144. [CrossRef] [PubMed]

54. Kussmaul, L.; Hirst, J. The mechanism of superoxide production by NADH:Ubiquinone oxidoreductase (complex I) from bovine heart mitochondria. Proc. Natl. Acad. Sci. USA 2006, 103, 7607–7612. [CrossRef] [PubMed]

55. Sazanov, L.A.; Hinchcliffe, P. Structure of the hydrophilic domain of respiratory complex I from Thermus thermophilus. Science 2006, 311, 1430–1436. [CrossRef]

56. Hoekstra, A.S.; Bayley, J.P. The role of complex II in disease. Biochim. Biophys. Acta 2013, 1827, 543–551. [CrossRef] [PubMed]
57. Quinlan, C.L.; Gerencser, A.A.; Treberg, J.R.; Brand, M.D. The mechanism of superoxide production by the antimycin-inhibited mitochondrial Q-cycle. *J. Biol. Chem.* 2011, 286, 31361–31372. [CrossRef] [PubMed]

58. Muller, F.L.; Liu, Y.; Van Remmen, H. Complex III releases superoxide to both sides of the inner mitochondrial membrane. *J. Biol. Chem.* 2004, 279, 49064–49073. [CrossRef]

59. Barja, G. Mitochondrial oxygen radical generation and leak: Sites of production in states 4 and 3, organ specificity, and relation to aging and longevity. *J. Bioenerg. Biomembr.* 1999, 31, 347–366. [CrossRef]

60. St-Pierre, J.; Buckingham, J.A.; Roebuck, S.J.; Brand, M.D. Topology of superoxide production from different sites in the mitochondrial electron transport chain. *J. Biol. Chem.* 2002, 277, 44784–44790. [CrossRef] [PubMed]

61. Cunha, F.M.; Caldeira da Silva, C.C.; Cerqueira, F.M.; Kowaltowski, A.J. Mild mitochondrial uncoupling as a therapeutic strategy. *Curr. Drug Targets* 2011, 12, 783–789. [CrossRef] [PubMed]

62. Skulachev, V.P. Uncoupling: New approaches to an old problem of bioenergetics. *Biochim. Biophys. Acta* 1998, 363, 100–124. [CrossRef]

63. Negre-Salvayre, A.; Hirtz, C.; Carrera, G.; Cazenave, R.; Troly, M.; Salavayre, R.; Penicaud, L.; Casteilla, L. A role for uncoupling protein-2 as a regulator of mitochondrial hydrogen peroxide generation. *FASEB J.* 1997, 11, 809–815. [CrossRef] [PubMed]

64. Jones, D.P. Intracellular diffusion gradients of O2 and ATP. *Am. J. Physiol.* 1986, 250, C663–C675. [CrossRef]

65. Wikstrom, M.; Krab, K.; Saraste, M. *Cytochrome Oxidase: A Synthesis*; Academic Press: London, UK, 1981.

66. Skulachev, V.P. Nonphosphorylating respiration as the mechanism preventing the formation of active forms of oxygen. *Mol. Biol. Mask.* 1995, 29, 1199–1209. [PubMed]

67. Boveris, A.; Chance, B. The mitochondrial generation of hydrogen peroxide: General properties and effect of hyperbaric oxygen. *Biochim. J.* 1973, 134, 707–716. [CrossRef]

68. Turrens, J.F.; Freeman, B.A.; Levitt, J.G.; Crapo, J.D. The effect of hyperoxia on superoxide production by lung submitochondrial particles. *Arch. Biochem. Biophys.* 1982, 217, 401–410. [CrossRef]

69. Gerschman, R.; Gilbert, D.L.; Nye, S.W.; Dwyer, P.; Fenn, W.O. Oxygen poisoning and x-irradiation: A mechanism in common. *Science* 1954, 119, 623–626. [CrossRef]

70. Kunin, A.P.; Bimpong-Buta, N.Y.; Vielhaber, S.; Elger, C.E.; Kunz, W.S. Characterization of superoxide-producing sites in isolated brain mitochondria. *J. Biol. Chem.* 2004, 279, 4127–4135. [CrossRef]

71. Hoffman, D.L.; Salter, J.D.; Brooks, P.S. Response of mitochondrial reactive oxygen species generation to steady-state oxygen tension: Implications for hypoxic cell signaling. *Am. J. Physiol. Heart Circ. Physiol.* 2007, 292, H101–H108. [CrossRef]

72. Skulachev, V.P. Role of uncoupled and non-coupled oxidations in maintenance of safely low levels of oxygen and its one-electron reductants. *Q. Rev. Biophys.* 1996, 29, 169–202. [CrossRef] [PubMed]

73. Erecinska, M.; Silver, I.A. Tissue oxygen tension and brain sensitivity to hypoxia. *Respir. Physiol.* 2001, 128, 263–276. [CrossRef]

74. Brown, G.C.; Cooper, C.E. Nanomolar concentrations of nitric oxide reversibly inhibit synaptosomal respiration by competing with oxygen at cytochrome oxidase. *FEBS Lett.* 1994, 356, 295–298. [CrossRef]

75. Mateo, J.; Garcia-Lecea, M.; Cadenas, S.; Hernandez, C.; Moncada, S. Regulation of hypoxia-inducible factor-1α by nitric oxide through mitochondrial dependent and -independent pathways. *Biochem. J.* 2003, 376, 537–544. [CrossRef]

76. Hagen, T.; Taylor, C.T.; Lam, F.; Moncada, S. Redistribution of intracellular oxygen in hypoxia by nitric oxide: Effect on HIF1alpha. *Science* 2003, 302, 1096–1109. [CrossRef] [PubMed]

77. Marcus, R.A.; Sutin, N. Electron transfers in chemistry and biology. *Biochim. Biophys. Acta* 1985, 811, 265–322. [CrossRef]

78. Moser, C.C.; Farid, T.A.; Chobot, S.E.; Dutton, P.L. Electron tunneling chains of mitochondria. *Biochim. Biophys. Acta* 2006, 1757, 1096–1109. [CrossRef]

79. Massey, V. Activation of molecular oxygen by flavins and flavoproteins. *J. Biol. Chem.* 1994, 269, 22459–22462. [CrossRef]

80. Kliman, J.P. How do enzymes activate oxygen without inactivating themselves? *Acc. Chem. Res.* 2007, 40, 325–333. [CrossRef] [PubMed]

81. Imlay, J.A. A metabolic enzyme that rapidly produces superoxide, fumarate reductase of Escherichia coli. *J. Biol. Chem.* 1995, 270, 19767–19777. [CrossRef]

82. Yang, M.; Yang, H.; Guan, H.; Bellier, J.P.; Zhao, S.; Tooyama, I. Mapping of mitochondrial ferritin in the brainstem of Macaca fascicularis. *Neuroscience* 2016, 328, 92–106. [CrossRef] [PubMed]

83. Drysdale, J.; Arosio, P.; Invernizzi, R.; Cazzola, M.; Volz, A.; Corsi, B.; Biasiotta, G.; Levi, S. Mitochondrial ferritin: A new player in iron metabolism. *Blood Cells Mol. Dis.* 2002, 29, 376–383. [CrossRef] [PubMed]

84. Levi, S.; Corsi, B.; Bosisio, M.; Invernizzi, R.; Volz, A.; Sanford, D.; Arosio, P.; Drysdale, J. A human mitochondrial ferritin encoded by an intronless gene. *J. Biol. Chem.* 2001, 276, 24437–24440. [CrossRef] [PubMed]

85. Drysdale, J.; Arosio, P. Mitochondrial ferritin. *Int. J. Biochem Cell Biol.* 2004, 36, 1887–1889. [CrossRef]

86. Li, X.; Wang, P.; Wu, Q.; Xie, L.; Cui, Y.; Li, H.; Yu, P.; Chang, Y.Z. The Construction and Characterization of Mitochondrial Ferritin Overexpressing Mice. *Int. J. Mol. Sci.* 2017, 8, 1518. [CrossRef] [PubMed]

87. Wang, P.; Cui, Y.; Ren, Q.; Yan, B.; Zhao, Y.; Yu, P.; Gao, G.; Shi, H.; Chang, S.; Chang, Y.Z. Mitochondrial ferritin attenuates cerebral ischaemia/reperfusion injury by inhibiting ferroptosis. *Cell Death Dis.* 2021, 12, 447. [CrossRef] [PubMed]

88. Fridovich, I. Superoxide radical and superoxide dismutases. *Annu. Rev. Biochem.* 1995, 64, 97–112. [CrossRef] [PubMed]
Antioxidants 2021, 10, 1824

98. Okado-Matsumoto, A.; Fridovich, I. Subcellular distribution of superoxide dismutases (SOD) in rat liver: Cu, Zn-SOD in mitochondria. J. Biol. Chem. 1993, 268, 3838–3839. [CrossRef] [PubMed]

99. Kawamata, H.; Manfredi, G. Different regulation of wild-type and mutant Cu, Zn superoxide dismutase localization in mammalian mitochondria. Hum. Mol. Genet. 2008, 17, 3303–3317. [CrossRef]

100. Salvi, M.; Battaglia, V.; Brunati, A.M.; La Rocca, N.; Tibaldi, E.; Pietrangeli, P.; Marcocci, L.; Mondovi, B.; Rossi, C.A.; Toninello, A.; Mdh et al. Mitochondrial disease in superoxide dismutase 2 knockout mice. Proc. Natl. Acad. Sci. USA 1999, 96, 846–851. [CrossRef] [PubMed]

101. Li, Y.; Huang, T.T.; Carlson, E.J.; Melov, S.; Ursell, P.C.; Olson, J.L.; Noble, L.J.; Yoshimura, M.P.; Berger, C.; Chan, P.H. Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. J. Biol. Chem. 2007, 282, 24407–24415. [CrossRef] [PubMed]

102. Du, A.; Dai, X.; Dong, J.; Liu, J.; Zhang, Y.; Fu, P.; Qin, H.; Li, R.; Zhang, R. Effects of aminoxyacetic acid on hippocampal mitochondria in rats with chronic alcoholism: The analysis of learning and memory-related genes. J. Integr. Neurosci. 2019, 18, 451–462. [PubMed]

103. Von Ossowski, I.; Hausner, G.; Loewen, P.C. Molecular evolutionary analysis based on the amino acid sequence of catalase. J. Mol. Evol. 1993, 37, 71–76. [CrossRef] [PubMed]

104. Deisseroth, A.; Dounce, A.L. Catalase: Physical and chemical properties, mechanism of catalysis, and physiological role. Physiol. Rev. 1970, 50, 319–375. [CrossRef] [PubMed]

105. Ivancich, A.; Jouve, H.M.; Sartor, B.; Gaillard, J. EPR investigation of compound I in Proteus mirabilis and bovine liver catalases: Formation of porphyrin and tyrosyl radical intermediates. Biochemistry 1997, 36, 9356–9364. [CrossRef] [PubMed]

106. Chance, B.; Sies, H.; Boveris, A. Hydroperoxide metabolism in mammalian organs. Physiol. Rev. 1979, 59, 527–605. [CrossRef] [PubMed]

107. Bakala, H.; Hamelin, M.; Mary, J.; Borot-Laloi, C.; Friguet, B. Catalase, a target of glycation damage in rat liver mitochondria with aging. Biochim. Biophys. Acta 2012, 1822, 1527–1537. [CrossRef] [PubMed]

108. Rindler, P.M.; Pfafker, S.M.; Szveda, L.I.; Kinter, M. High dietary fat selectively increases catalase expression within cardiac mitochondria. J. Biol. Chem. 2013, 288, 1979–1990. [CrossRef] [PubMed]

109. Rindler, P.M.; Cacciola, A.; Kinter, M.; Szveda, L.I. Catalase-dependent H2O2 consumption by cardiac mitochondria and redox-mediated loss in insulin signaling. Am. J. Physiol. Heart Circ. Physiol. 2016, 311, H1091–H1096. [CrossRef] [PubMed]

110. Brigelius-Flohe, R.; Flohé, L. Selenium and redox signaling. Arch. Biochem. Biophys. 2017, 617, 48–59. [CrossRef] [PubMed]

111. Toppo, S.; Flohé, L.; Ursini, F.; Vanin, S.; Maiorino, M. Catalytic mechanisms and specificities of glutathione peroxidases: Variations of a basic scheme. Biochim. Biophys. Acta 2009, 1790, 1486–1500. [CrossRef]

112. Flohé, L.; Toppo, S.; Cozza, G.; Ursini, F. A comparison of thiol peroxidase mechanisms. Antioxid. Redox Signal. 2011, 15, 763–780. [CrossRef] [PubMed]

113. Flohé, L. The Selenoprotein Glutathione Peroxidase; Poulson, R.D., Aramovic, O., Eds.; John Wiley & Sons Inc.: New York, NY, USA, 1989.

114. Esposito, L.A.; Kokoszka, J.E.; Waymire, K.G.; Cottrell, B.; MacGregor, G.R.; Wallace, D.C. Mitochondrial oxidative stress in mice lacking the glutathione peroxidase-1 gene. Free Radic. Biol. Med. 2000, 28, 754–766. [CrossRef] [PubMed]

115. Ursini, F.; Maiorino, M.; Brigelius-Flohe, R.; Aumann, K.D.; Roveri, A.; Schomburg, D.; Flohe, L. Diversity of glutathione peroxidases. Methods Enzymol. 1995, 252, 38–53. [PubMed] [CrossRef]

116. Brigelius-Flohe, R.; Maiorino, M. Glutathione peroxidases. Biochim. Biophys. Acta 2013, 1830, 3289–3303. [CrossRef] [PubMed] [CrossRef]
Antioxidants 2021, 10, 1824

117. Chen, Y.; Zhang, H.; Zhou, H.J.; Ji, W.; Min, W. Mitochondrial Redox Signaling and Tumor Progression. Cancers 2016, 8, 40. [CrossRef]

118. Schneider, M.; Förster, H.; Boersma, A.; Seiler, A.; Wehnes, H.; Sinowatz, F.; Neumüller, C.; Deutsch, M.J.; Walch, A.; Hrabé de Angelis, M.; et al. Mitochondrial glutathione peroxidase 4 disruption causes male infertility. FASEB J. 2009, 23, 3233–3242. [CrossRef]

119. Olafsdóttir, K.; Reed, D.J. Retention of oxidized glutathione by isolated rat liver mitochondria during hydroperoxide treatment. Biochim. Biophys. Acta 1988, 964, 377–382. [CrossRef]

120. Couto, N.; Wood, J.; Barber, J. The role of glutathione reductase and related enzymes on cellular redox homeostasis network. Free Radic. Biol. Med. 2016, 95, 27–42. [CrossRef]

121. Outten, C.E.; Culotta, V.C. Alternative start sites in the Saccharomyces cerevisiae GLR1 gene are responsible for mitochondrial and cytosolic isoforms of glutathione reductase. J. Biol. Chem. 2004, 279, 7785–7791. [CrossRef]

122. Couto, N.; Malys, N.; Gaskell, S.J.; Barber, J. Partition and turnover of glutathione reductase from Saccharomyces cerevisiae: A proteomic approach. J. Proteome Res. 2013, 12, 2885–2894. [CrossRef]

123. Ge, C.; Spänning, E.; Glaser, E.; Wieslander, A. Import determinants of organelle-specific and dual targeting peptides of mitochondria and chloroplasts in Arabidopsis thaliana. Mol. Plant. 2014, 7, 121–136. [PubMed] [CrossRef]

124. Kelner, M.J.; Montoya, M.A. Structural organization of the human glutathione reductase gene: Determination of correct cDNA sequence and identification of a mitochondrial leader sequence. Biochem. Biophys. Res. Commun. 2000, 269, 366–368. [CrossRef] [PubMed]

125. Holmgren, A.; Lu, J. Thioredoxin and thioredoxin reductase: Current research with special reference to human disease. Biochem. Biophys. Res. Commun. 2010, 396, 120–124. [CrossRef]

126. Lu, J.; Holmgren, A. The thioredoxin antioxidant system. Free Radic. Biol. Med. 2014, 66, 75–87. [CrossRef]

127. Arner, E.S. Focus on mammalian thioredoxin reductases—Important selenoproteins with versatile functions. Biochim. Biophys. Acta 2009, 1792, 1–20. [CrossRef]

128. Arner, E.S. Physiological functions of thioredoxin and thioredoxin reductase. Eur. J. Biochem. 2000, 267, 6102–6109. [CrossRef]

129. Zhang, H.; Luo, Y.; Zhang, W.; He, Y.; Dai, S.; Zhang, R.; Huang, Y.; Bernatchez, P.; Giordano, F.J.; Shadel, G.; et al. Endothelial-specific expression of mitochondrial thioredoxin improves endothelial cell function and reduces atherosclerotic lesions. Am. J. Pathol. 2007, 170, 1108–1120. [CrossRef]

130. Ribas, V.; García-Ruiz, C.; Fernández-Checa, J.C. Glutathione and mitochondria. Front. Pharmacol. 2014, 5, 151.

131. Hansen, J.M.; Zhang, H.; Jones, D.P. Differential oxidation of thioredoxin-1, thioredoxin-2, and glutathione by metal ions. Free Radic. Biol. Med. 2006, 40, 138–145. [CrossRef] [PubMed]

132. Watson, W.H.; Jones, D.P. Oxidation of nuclear thioredoxin during oxidative stress. FEBS Lett. 2003, 543, 144–147. [CrossRef]

133. Rhee, S.G.; Kil, I.S. Multiple Functions and Regulation of Mammalian Peroxiredoxins. Annu. Rev. Biochem. 2017, 86, 749–775. [CrossRef] [PubMed]

134. Wood, Z.A.; Schroeder, E.; Robin Harris, J.; Poole, L.B. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem. Sci. 2003, 28, 32–40. [CrossRef]

135. Zeida, A.; Trujillo, M.; Ferrer-Sueta, G.; Denicola, A.; Estrin, D.A.; Radi, R. Catalysis of Peroxide Reduction by Fast Reacting Protein Thiols. Chem. Rev. 2019, 119, 10829–10855. [CrossRef] [PubMed]

136. Dubuisson, M.; Vander Stricht, D.; Clippé, A.; Etienne, F.; Nauser, T.; Kissner, R.; Koppenol, W.H.; Rees, J.F.; Knoops, B.; N. Human peroxiredoxin 5 is a peroxynitrite reductase. FEBS Lett. 2004, 571, 161–165. [CrossRef] [PubMed]

137. Trujillo, M.; Clippé, A.; Manta, B.; Ferrer-Sueta, G.; Smeets, A.; Declercq, J.P.; Knoops, B.; Radi, R. Pre-steady state kinetic characterization of human peroxiredoxin 5: Taking advantage of Trp84 fluorescence increase upon oxidation. Arch. Biochem. Biophys. 2007, 467, 95–106. [CrossRef] [PubMed]

138. De Armas, M.I.; Esteves, R.; Viera, N.; Reyes, A.M.; Mastrogianni, M.; Allegria, T.G.P.; Netto, L.E.S.; Tortora, V.; Radi, R.; Trujillo, M. Rapid peroxynitrite reduction by human peroxiredoxin 3: Implications for the fate of oxidants in mitochondria. Free Radic. Biol. Med. 2019, 130, 369–378. [CrossRef]

139. Kameritsch, P.; Singer, M.; Nuernbergk, C.; Rios, N.; Reyes, A.M.; Schmidt, K.; Kirsch, J.; Schneider, H.; Müller, S.; Pogoda, K.; et al. The mitochondrial thioredoxin reductase system (TrxR2) in vascular endothelium controls peroxynitrite levels and tissue integrity. Proc. Natl. Acad. Sci. USA 2021, 118, e1921828118. [CrossRef] [PubMed]

140. Cox, A.G.; Winterbourn, C.C.; Hampton, M.B. Mitochondrial peroxiredoxin involvement in antioxidant defence and redox signalling. Biochem. J. 2010, 425, 313–325. [CrossRef]

141. Pollak, N.; Dölle, C.; Ziegler, M. The power to reduce: Pyridine nucleotides—Small molecule swith a multitude of functions. Biochem. J. 2007, 402, 205–218. [CrossRef]

142. Rydström, J.; Hoek, J.B.; Ernstner, L. Nicotinamide nucleotide transhydrogenases. In The Enzymes; Boyer, P.D., Ed.; Academic Press: New York, NY, USA, 1976; pp. 51–88.

143. Meister, A.; Anderson, M.E.; Hwang, O. Intracellular cysteine and glutathione delivery systems. J. Am. Coll. Nutr. 1986, 5, 137–151. [CrossRef] [PubMed]

144. Oestreicher, J.; Morgan, B. Glutathione: Subcellular distribution and membrane transport. Biochem. Cell Biol. 2019, 97, 270–289. [CrossRef]
145. Mari, M.; Morales, A.; Colell, A.; Garcia-Ruiz, C.; Fernandez-Checa, J.C. Mitochondrial glutathione, a key survival antioxidant. *Antioxid. Redox. Signal.* 2009, 1, 2685–2700. [CrossRef]

146. Griffith, O.W.; Meister, A. Origin and turnover of mitochondrial glutathione. *PNAS* 1985, 82, 4668–4672. [CrossRef]

147. Chen, Z.; Lash, L.H. Evidence for mitochondrial uptake of glutathione by dicarboxylate and 2-oxoglutarate carriers. *J. Pharmacol. Exp. Therap.* 1998, 285, 608–618.

148. Chen, Z.; Putt, D.A.; Lash, L.H. Enrichment and functional reconstitution of glutathione transport activity from rabbit kidney mitochondria. Further evidence for the role of the dicarboxylate and 2-oxoglutarate carriers in mitochondrial glutathione transport. *Arch. Biochem. Biophys.* 2000, 373, 193–202. [CrossRef]

149. Lash, L.H. Mitochondrial glutathione transport: Physiological, pathological and toxicological implications. *Chem. Biol. Interact.* 2006, 163, 54–67. [CrossRef]

150. Coll, O.; Colell, A.; Garcia-Ruiz, C.; Kaplowitz, N.; Fernández-Checa, J.C. Sensitivity of the 2-oxoglutarate carrier to alcohol intake contributes to mitochondrial glutathione depletion. *Hepatology* 2003, 38, 692–702. [CrossRef]

151. Mari, M.; de Gregorio, E.; de Dios, C.; Roca-Agujetas, V.; Cucarull, B.; Tutusaus, A.; Morales, A.; Colell, A. Mitochondrial Glutathione: Recent Insights and Role in Disease. *Antioxidants* 2020, 9, 909. [CrossRef]

152. Armeni, T.; Cianfruglia, L.; Piva, F.; Urbanelli, L.; Luisa Caniglia, M.; Pugnaloni, A.; Principato, G. S-D-Lactoylglutathione can be an alternative supply of mitochondrial glutathione. *Free Radic. Biol. Med.* 2014, 67, 451–459. [CrossRef]

153. Rydström, J. Mitochondrial NADPH, transhydrogenase and disease. *Biochim. Biophys. Acta* 2006, 1757, 721–726. [CrossRef]

154. Quinzii, C.M.; Hirano, M. Coenzyme Q and mitochondrial disease. *Dev. Disabl. Res. Rev.* 2010, 16, 183–188. [CrossRef]

155. Olson, R.E.; Rudney, H. Biosynthesis of ubiquinone. *Vitam. Horm.* 1983, 40, 1–43.

156. Ernst, L.; Dallner, G. Biochemical, physiological and medical aspects of ubiquinone function. *Biochim. Biophys. Acta* 1995, 1271, 195–204. [CrossRef]

157. Ha, S.; Lee, J.; Clarke, C.F. Genetic evidence for a multi-subunit complex in the O-methyltransferase steps of coenzyme Q biosynthesis. *Biochim. Biophys. Acta* 2000, 1484, 287–297. [CrossRef]

158. Bentinger, M.; Dallner, G.; Chojnacki, T.; Swiezewska, E. Distribution and breakdown of labeled coenzyme Q10 in rat. *Free Radic. Biol. Med.* 2003, 34, 563–575. [CrossRef]

159. Kemmerer, Z.A.; Robinson, K.P.; Schmitz, J.M.; Manicki, M.; Paulson, B.R.; Jochem, A.; Hutchins, P.D.; Coon, J.J.; Pagliarini, D.J. UbiB proteins regulate cellular CoQ distribution. *Biochim. Biophys. Acta* 2000, 1484, 287–297. [CrossRef]

160. Turunen, M.; Olsson, J.; Dallner, G. Metabolism and function of coenzyme Q. *Biochim. Biophys. Acta* 2004, 1660, 171–199. [CrossRef]

161. Mellors, A.; Tappel, A.L. The inhibition of mitochondrial peroxidation by ubiquinone and ubiquinol. *J. Biol. Chem.* 1966, 241, 4353–4355. [CrossRef]

162. Gutierrez-Mariscal, F.M.; de la Cruz-Ares, S.; Torres-Peña, J.D.; Alcalá-Díaz, J.F.; Yubero-Serrano, E.M.; López-Miranda, J. Coenzyme Q10 and Cardiovascular Diseases. *Antioxidants* 2021, 10, 906. [CrossRef]

163. Echty, K.S.; Winkler, E.; Klingenberg, M. Coenzyme Q Is an Obligatory Cofactor for Uncoupling Protein Function. *Nature* 2000, 408, 609–613. [CrossRef]

164. Echty, K.S.; Winkler, E.; Frischmuth, K.; Klingenberg, M. Uncoupling proteins 2 and 3 are highly active H+ transporters and highly nucleotide sensitive when activated by coenzyme Q (ubiquinone). *Proc. Natl. Acad. Sci. USA* 2001, 98, 1416–1421. [CrossRef][PubMed]

165. Sahach, V.F.; Vavilova, H.L.; Rudyk, O.V.; Dobrovol’skiyi, F.V.; Shymans’ka, T.V.; Miedwiediev, O.S. Inhibition of Mitochondrial Permeability Transition Pois Is One of the Mechanisms of Cardioprotective Effect of Coenzyme Q10. *Fiziol. Zh.* 2007, 53, 35–42.

166. Papucci, L.; Schiavone, N.; Witort, E.; Donnini, M.; Pugnaloni, A.; Tempestini, A.; Formigli, L.; Zecchi-Orlandini, S.; Orlandini, G.; Carella, G.; et al. Coenzyme Q10 Prevents Apoptosis by Inhibiting Mitochondrial Depolarization Independently of Its Free Radical Scavenging Property. *J. Biol. Chem.* 2003, 278, 28220–28228. [CrossRef][PubMed]

167. Bruno, E.J., Jr; Ziegenfuss, T.N.; Landis, J. Vitamin C: Research update. *Curr. Sports Med. Rep.* 2006, 5, 177–181. [CrossRef]

168. Nishikimi, M.; Yagi, K. Molecular basis for the deficiency in humans of gulonolactone oxidase, a key enzyme for ascorbic acid biosynthesis. *Am. J. Clin. Nutr.* 1991, 54, 1203S–1208S. [CrossRef][PubMed]

169. Li, Y. *Antioxidants in Biology and Medicine: Essentials, Advances, and Clinical Applications*; Nova Science: New York, NY, USA, 2001.

170. Lykkefsfeldt, J. On the effect of vitamin C intake on human health: How to (mis)interpret the clinical evidence. *Redox Biol.* 2020, 34, 101532. [CrossRef]

171. Wilson, J.X. Regulation of vitamin C transport. *Annu. Rev. Nutr.* 2005, 25, 105–125. [CrossRef]

172. Ramanathan, K.; Shila, S.; Kumaran, S.; Panneerselvam, C. Ascorbic acid and alpha-tocopherol as potent modulators on arsenic induced toxicity in mitochondria. *J. Nutr. Biochem.* 2003, 14, 416–420. [CrossRef]

173. Ingebretsen, O.C.; Normann, P.T. Transport of ascorbate into guinea pig liver mitochondria. *Biochim. Biophys. Acta* 1982, 684, 21–26. [CrossRef]

174. Li, X.; Cobb, C.E.; Hill, K.E.; Burk, R.F.; May, J.M. Mitochondrial uptake of glutathione via facilitative glucose transporter 1 (Glut1) and confers mitochondrial protection against oxidative injury. *FASEB J.* 2005, 19, 1657–1667.
Antioxidants 2021, 10, 1824

27 of 29

176. Lee, Y.C.; Huang, H.Y.; Chang, C.J.; Cheng, C.H.; Chen, Y.T. Mitochondrial GLUT10 facilitates dehydroascorbic acid import and protects cells against oxidative stress: Mechanistic insight into arterial tortuosity syndrome. Hum. Mol. Genet. 2010, 19, 3721–3733. [CrossRef]

177. Scalera, V.; Giangregorio, N.; De Leonardiis, S.; Console, L.; Carulli, E.S.; Tonazzi, A. Characterization of a Novel Mitochondrial Ascorbate Transporter from Rat Liver and Potato Mitochondria. Front. Mol. Biosci. 2018, 26, 5–38. [CrossRef]

178. Bánhegyi, G.; Benedetti, A.; Margittai, E.; Marcelongo, P.; Fulcieri, R.; Németh, C.E.; Szarka, A. Subcellular compartmentation of ascorbate and its variation in disease states. Biochim. Biophys. Acta 2014, 1843, 1909–1916. [CrossRef]

179. Shahidi, F.; de Camargo, A.C. Tocopherols and tocotrienols in common and emerging 486 dietary sources: Occurrence, applications, and health benefits. Int. J. Mol. Sci. 2016, 17, 1745. [CrossRef][PubMed]

180. Niki, E.; Abe, K. Vitamin E: Structure, properties and functions. In Vitamin E: Chemistry and Nutritional Benefits; Royal Society of Chemistry: London, UK, 2019; pp. 1–11.

181. Chung, S.; Ghelfi, M.; Atkinson, J.; Parker, R.; Qian, J.; Carlin, C.; Manor, D. Vitamin E and phosphoinositides regulate the intracellular localization of the hepatic α-tocopherol transfer protein. J. Biol. Chem. 2016, 291, 17028–17039. [CrossRef][PubMed]

182. Qian, J.; Morley, S.; Wilson, K.; Nava, P.; Atkinson, J.; Manor, D. Intracellular trafficking of vitamin E in hepatocytes: Role of tocopherol transfer protein. J. Lipid Res. 2005, 46, 2072–2082. [CrossRef]

183. Horiguchi, M.; Arita, M.; Kaempf-Rotzol, D.E.; Tsujimoto, M.; Inoue, K.; Arai, H. pH dependent translocation of α-tocopherol transfer protein (α-TTP) between hepatic cytosol and late endosomes. Genes Cells 2003, 8, 789–800. [CrossRef]

184. Jiang, Q. Natural forms of vitamin E: Metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy. Free Radic. Biol. Med. 2014, 72, 76–90. [CrossRef]

185. Niki, E. Role of vitamin E as a lipid-soluble peroxyl radical scavenger: In vitro and in vivo evidence. Free Radic. Biol. Med. 2014, 66, 3–12. [CrossRef]

186. Mardones, P.; Rigotti, A. Cellular mechanisms of vitamin E uptake: Relevance in alpha-tocopherol metabolism and potential implications for disease. J. Nutr. Biochem. 2004, 15, 252–260. [CrossRef]

187. Buttriss, J.L.; Diplock, A.T. The alpha-tocopherol and phospholipid fatty acid content of rat liver subcellular membranes in vitamin E and selenium deficiency. Biochim. Biophys. Acta 1988, 963, 61–69. [CrossRef]

188. Mustacich, D.J.; Leonard, S.W.; Patel, N.K.; Traber, M.G. α-tocopherol β-oxidation localized to rat liver mitochondria. Free Radic. Biol. Med. 2010, 48, 73–81. [CrossRef][PubMed]

189. Saito, Y.; Yoshida, Y.; Nishio, K.; Hayakawa, M.; Ogawa, Y.; Sakamoto, H.; Fujii, K.; Yoshida, Y.; Niki, E. Characterization of cellular uptake and distribution of coenzyme Q10 and vitamin E in PC12 cells. J. Nutr. Biochem. 2009, 20, 350–357. [CrossRef][PubMed]

190. Saito, Y.; Yoshida, Y.; Nishio, K.; Hayakawa, M.; Niki, E. Characterization of cellular uptake and distribution of vitamin E. Annu. N. Y. Acad. Sci. 2004, 1031, 368–375. [CrossRef]

191. Yévenes, L.F.; Klein, A.; Castro, J.F.; Marin, T.; Leal, N.; Leighton, F.; Alvarez, A.R.; Zanlungo, S. Lysosomal vitamin E accumulation in Niemann–Pick type C disease. Biochim. Biophys. Acta 2012, 1822, 150–160. [CrossRef][PubMed]

192. Venditti, P.; Napolitano, G.; Barone, D.; Di Meo, S. Effect of training and vitamin E administration on rat liver oxidative metabolism. Free Radic. Res. 2014, 48, 322–332. [CrossRef][PubMed]

193. Venditti, P.; Napolitano, G.; Barone, D.; Di Meo, S. Vitamin E supplementation modifies adaptive responses to training in rat skeletal muscle. Free Radic. Res. 2014, 48, 1179–1189. [CrossRef]

194. Venditti, P.; Napolitano, G.; Barone, D.; Pervito, E.; Di Meo, S. Vitamin E-enriched diet reduces adaptive responses to training determining respiratory capacity and redox homeostasis in rat heart. Free Radic. Res. 2016, 50, 56–67. [CrossRef]

195. Irias-Mata, A.; Sus, N.; Flory, S.; Stock, D.; Woerner, D.; Podszun, M.; Frank, J. α-Tocopherol transfer protein does not regulate the cellular uptake and intracellular distribution of α- and γ-tocopherols and -tocotrienols in cultured liver cells. Redox Biol. 2018, 19, 28–36. [CrossRef]

196. Mukai, K.; Ishikawa, E.; Ouchi, A.; Nagaoka, S.I.; Abe, K.; Suzuki, T.; Izumisawa, K. Measurements of Singlet Oxygen-Quenching Activity of Vitamin E Homologs and Palm Oil and Soybean Extracts in a Micellar Solution. Lipoths 2018, 53, 601–613. [CrossRef][PubMed]

197. Munné-Bosch, S. The role of alpha-tocopherol in plant stress tolerance. J. Plant. Physiol. 2005, 162, 743–748. [CrossRef][PubMed]

198. Gotoh, N.; Niki, E. Rates of interactions of superoxide with vitamin E, vitamin C and related compounds as measured by chemiluminescence. Biochim. Biophys. Acta 1992, 1115, 201–207. [CrossRef]

199. Cadenas, E.; Merenyi, G.; Lind, J. Pulse radiolysis study of the reactivity of Trolox C phenoxyl radical with superoxide anion. FEBS Lett. 1989, 253, 235–241. [CrossRef]

200. Lass, A.; Sohal, R.S. Effect of coenzyme Q (10) and α-tocopherol content of mitochondria on the production of superoxide anion radicals. FASEB J. 2000, 14, 87–94. [CrossRef][PubMed]

201. Chow, C.K.; Ibrahim, W.; Wei, Z.; Chan, A.C. Vitamin E regulates mitochondrial hydrogen peroxide generation. Free Radic. Biol. Med. 2000, 27, 580–587. [CrossRef]

202. Wang, X.; Quinn, P.J. Vitamin E and its function in membranes. Prog. Lipid. Res. 1999, 38, 309–336. [CrossRef]

203. Kim, S.H.; Kim, H. Inhibitory Effect of Astaxanthin on Oxidative Stress-Induced Mitochondrial Dysfunction-A Mini-Review. Nutrients 2018, 10, 1137. [CrossRef]
204. Schlame, M.; Greenberg, M.L. Biosynthesis, remodeling and turnover of mitochondrial cardiolipin. *BBA-Mol. Cell. Biol. Lipids*. 2017, 1862, 3–7. [CrossRef]

205. Shen, Z.; Ye, C.; McCain, K.; Greenberg, M.L. The role of cardiolipin in cardiovascular health. *Biomed. Res. Int.* 2015, 2015, 12. [CrossRef]

206. Ademowo, O.S.; Dias, H.K.I.; Burton, D.G.A.; Griffiths, H.R. Lipid (per) oxidation in mitochondria: An emerging target in the aging process? *Biogerontology* 2017, 18, 859–879. [CrossRef]

207. Wu, J.; Wang, Y.; Jiang, R.; Xue, R.; Yin, X.; Wu, M.; Meng, Q. Ferroptosis in liver disease: New insights into disease mechanisms. *Cell. Death Discov.* 2021, 7, 276. [CrossRef]

208. Liang, H.; Van Remmen, H.; Frohlich, V.; Lechleiter, J.; Richardson, A.; Ran, Q. Gpx4 protects mitochondrial ATP generation against oxidative damage. *Biochem. Biophys. Res. Commun.* 2007, 356, 893–898. [CrossRef] [PubMed]

209. Mao, C.; Liu, X.; Zhang, Y.; Lei, G.; Yan, Y.; Lee, H.; Koppula, P.; Wu, S.; Zhuang, L.; Fang, B.; et al. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer. *Nature* 2021, 593, 586–590. [CrossRef]

210. Quiros, P.M.; Langer, T.; Lopez Otin, C. New roles for mitochondrial proteases in health, aging, and disease. *Nat. Rev. Mol. Cell. Biol.* 2015, 16, 345–359. [CrossRef]

211. Zeng, L.; Tan, J.; Lu, W.; Lu, T.; Hu, Z. The potential role of small heat shock proteins in mitochondria. *Cell Signal.* 2013, 25, 2312–2319. [CrossRef] [PubMed]

212. Tatsuta, T.; Langer, T. AAA proteases in mitochondria: Diverse functions of membrane bound of proteolytic machines. *Res. Microbiol.* 2009, 160, 711–717. [CrossRef] [PubMed]

213. Käser, M.; Kambacheld, M.; Kisters Woike, B.; Langer, T. Oma1, a novel membrane bound metallopeptidase in mitochondria with activities overlapping with the mAAAprotease. *J. Biol. Chem.* 2003, 278, 46414–46423. [CrossRef] [PubMed]

214. Bota, D.A.; Davies, K.J. Lon protease preferentially degrades oxidized mitochondrial aconitase by an ATP stimulated mechanism. *Nat. Cell. Biol.* 2002, 4, 674–680. [CrossRef]

215. Bender, T.; Lewrenz, I.; Franken, S.; Baitzel, C.; Voos, W. Mitochondrial enzymes are protected from stress induced aggregation by mitochondrial chaperones and the Pim1/LON protease. *Mol. Biol. Cell.* 2011, 22, 541–554. [CrossRef] [PubMed]

216. Bulteau, A.L.; Szveda, L.I.; Friguet, B. Mitochondrial protein oxidation and degradation in response to oxidative stress and aging. *Exp. Gerontol.* 2006, 41, 653–657. [CrossRef]

217. De, B.R.; Van, L.N. Endogenous DNA damage in humans: A review of quantitative data. *Mutagenesis* 2004, 19, 169–185.

218. Lindahl, T. Instability and decay of the primary structure of DNA. *Nature* 1993, 362, 709–715. [CrossRef] [PubMed]

219. Lee, S.R.; Han, J. Mitochondrial Nucleoid: Shield and Switch of the Mitochondrial Genome. *Oxid Med Cell Longev.* 2017, 2017, 8060949. [CrossRef]

220. DiMauro, S.; Schon, E.A. Mitochondrial respiratory-chain diseases. *N. Engl. J. Med.* 2003, 348, 2656–2668. [CrossRef]

221. Allkanjari, K.; Balduck, R.A. Beyond Base Excision Repair: An evolving picture of mitochondrial DNA repair. *Biosci. Rep.* 2021, 41, 20211320. [CrossRef] [PubMed]

222. Muftuoglu, M.; Mori, M.P.; de Souza-Pinto, N.C. Formation and repair of oxidative damage in the mitochondrial DNA. *Mitochondrion* 2014, 17, 164–181. [CrossRef]

223. Dahal, S.; Dubey, S.; Raghavan, S.C. Homologous recombination-mediated repair of DNA double-strand breaks operates in mammalian mitochondria. *Cell. Mol. Life Sci.* 2018, 75, 1641–1655. [CrossRef] [PubMed]

224. Tadi, S.K.; Sebastian, R.; Dahal, S.; Babu, R.K.; Choudhary, B.; Raghavan, S.C. Microhomology-mediated end joining is the principal mediator of double-strand break repair during mitochondrial DNA lesions. *Mol. Biol. Cell.* 2016, 27, 223–235. [CrossRef] [PubMed]

225. Kansanen, E.; Jyrkkänen, H.K.; Levonen, A.L. Activation of stress signaling pathways by electrolyphic oxidized and nitrated lipids. *Free Radic. Biol. Med.* 2012, 52, 973–982. [CrossRef]

226. Kansanen, E.; Kivelä, A.M.; Levonen, A.L. Regulation of Nrf2-dependent gene expression by 15-deoxy-Delta12,14-prostaglandin J2. *Free Radic. Biol. Med.* 2009, 47, 1310–1317. [CrossRef]

227. Bryan, H.K.; Olayanju, A.; Goldring, C.E.; Park, B.K. The Nrf2 cell defence pathway: Keap1-dependent and independent mechanisms of regulation. *Biochem. Pharmacol.* 2013, 85, 705–717. [CrossRef]

228. Nguyen, T.; Sherratt, P.J.; Pickett, C.B. Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. *Annu. Rev. Pharmacol. Toxicol.* 2003, 43, 233–260.

229. Itoh, K.; Chiba, T.; Takahashi, S.; Ishii, T.; Igarashi, K.; Katoh, Y. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. *Biochem. Biophys. Res. Commun.* 1997, 236, 313–322. [CrossRef] [PubMed]

230. Nguyen, T.; Sherratt, P.J.; Nioi, P.; Yang, C.S.; Pickett, C.B. Nrf2 controls constitutive and inducible expression of ARE-driven genes through a dynamic pathway involving nucleocytoplasmic shuttling by Keap1. *J. Biol. Chem.* 2005, 280, 32485–32492. [CrossRef]

231. Tebay, L.E.; Robertson, H.; Durant, S.T.; Vitale, S.R.; Penning, T.M.; Dinkova-Kostova, A.T.; Hayes, J.D. Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease. *Free Radic. Biol. Med.* 2015, 88 Pt B, 108–146. [CrossRef]

232. Ryoo, I.G.; Kwak, M.K. Regulatory crosstalk between the oxidative stress-related transcription factor Nfe2l2/Nrf2 and mitochondria. *Toxicol. Appl. Pharm.* 2018, 359, 24–33. [CrossRef]
233. Cherry, A.D.; Suliman, H.B.; Bartz, R.R.; Piantadosi, C.A. Peroxisome proliferator-activated receptor gamma co-activator 1- as a critical co-activator of the murine hepatic oxidative stress response and mitochondrial biogenesis in Staphylococcus aureus sepsis. J. Biol. Chem. 2014, 289, 41–52. [CrossRef] [PubMed]

234. Miyamoto, N.; Izumi, H.; Miyamoto, R.; Kondo, H.; Tawara, A.; Sasaguri, Y.; Kohno, K. Quercetin induces the expression of peroxiredoxins 3 and 5 via the Nrf2/NRF1 transcription pathway. Invest. Ophthalmol. Vis. Sci. 2011, 52, 1055–1063. [CrossRef]

235. Tsushima, M.; Liu, J.; Hirao, W.; Yamazaki, H.; Tomita, H.; Itoh, K. Emerging evidence for crosstalk between Nrf2 and mitochondria in physiological homeostasis and in heart disease. Arch. Pharm. Res. 2020, 43, 286–296. [CrossRef] [PubMed]

236. Holmstrom, K.M.; Kostovm, R.V.; Dinkova-Kostova, A.T. The multifaceted role of Nrf2 in mitochondrial function. Curr. Opin. Toxicol. 2016, 1, 80–91. [CrossRef]

237. Kasai, S.; Yamazaki, H.; Tanji, K.; Engler, M.J.; Matsumiya, T.; Itoh, K. Role of the ISR-ATF4 pathway and its cross talk with Nrf2 in mitochondrial quality control. J. Clin. Biochem. Nutr. 2019, 64, 1–12. [CrossRef] [PubMed]

238. Ludtmann, M.H.; Angelova, P.R.; Zhang, Y.; Abramov, A.Y.; Dinkova-Kostova, A.T. Nrf2 affects the efficiency of mitochondrial fatty acid oxidation. Biochem. J. 2014, 457, 415–424. [CrossRef] [PubMed]

239. Anedda, A.; Lopez-Bernardo, E.; Acosta-Iborra, B.; Saadeh Suleiman, M.; Landazuri, M.O.; Cadenas, S. The transcription factor Nrf2 promotes survival by enhancing the expression of uncoupling protein 3 under conditions of oxidative stress. Free Radic. Biol. Med. 2013, 61, 395–407. [CrossRef] [PubMed]

240. Hu, Q.; Ren, J.; Li, G.; Wu, J.; Wu, X.; Wang, G.; Gu, G.; Ren, H.; Hong, Z.; Li, J. The mitochondrially targeted antioxidant MitoQ protects the intestinal barrier by ameliorating mitochondrial DNA damage via the Nrf2/ARE signaling pathway. Cell Death Dis. 2018, 9, 403. [CrossRef] [PubMed]

241. He, F.; Ru, X.; Wen, T. NRF2, a Transcription Factor for Stress Response and Beyond. Int. J. Mol. Sci. 2020, 21, 4777. [CrossRef]

242. Piantadosi, C.A.; Carraway, M.S.; Babiker, A.; Suliman, H.B. Heme oxygenase-1 regulates cardiac mitochondrial biogenesis via Nrf2-mediated transcriptional control of nuclear respiratory factor-1. Circ. Res. 2008, 103, 1232–1240. [CrossRef]

243. Virbanius, J.V.; Scarpulla, R.C. Activation of the human mitochondrial transcription factor a gene by nuclear respiratory factors: A potential regulatory link between nuclear and mitochondrial expression in mitochondrial biogenesis. Proc. Natl. Acad. Sci. USA 1994, 91, 1309–1313. [CrossRef]

244. Murata, H.; Takamatsu, H.; Liu, S.; Kataoka, K.; Huh, N.H.; Sakaguchi, M. Nrf2 Regulates PINK1 Expression under oxidative stress conditions. PLoS ONE 2015, 10, e0142438. [CrossRef]

245. Narendra, D.P.; Jin, S.M.; Tanaka, A.; Suen, D.F.; Youle, R.J. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J. Cell Biol. 2008, 183, 795–803. [CrossRef] [PubMed]

246. Narendra, D.P.; Jin, S.M.; Tanaka, A.; Suen, D.F.; Gautier, C.A.; Shen, J.; Cookson, M.R.; Youle, R.J. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol. 2010, 8, e1000298. [CrossRef] [PubMed]

247. Matsuda, N.; Sato, S.; Shiba, K.; Okatsu, K.; Saiasho, K.; Gouitier, C.A.; Sou, Y.S.; Saiki, S.; Kawajiri, S.; Sato, F.; et al. PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J. Cell Biol. 2010, 189, 211–221. [CrossRef]

248. Kasai, S.; Shimizu, S.; Tatara, Y.; Mimura, J.; Itoh, K. Regulation of Nrf2 by Mitochondrial Reactive Oxygen Species in Physiology and Pathology. Biomolecules 2020, 10, 320. [CrossRef]

249. Zoccarato, F.; Cavallini, L.; Alexandre, A. Respiration-dependent removal of exogenous H2O2 in brain mitochondria. J. Biol. Chem. 2004, 279, 4166–4174. [CrossRef]

250. Drechsel, D.A.; Patel, M. Respiration dependent H2O2 removal in brain mitochondria via thioredoxin/peroxiredoxin system. J. Biol. Chem. 2010, 285, 27850–27858. [CrossRef] [PubMed]

251. Venditti, P.; Napolitano, G.; Barone, D.; Coppola, I.; Di Meo, S. Effect of thyroid state on enzymatic and non-enzymatic processes in H2O2 removal by liver mitochondria of male rats. Mol. Cell. Endocrinol. 2015, 403, 57–63. [CrossRef] [PubMed]

252. Venditti, P.; Napolitano, G.; Fasciolo, G.; Di Meo, S. Thyroid state affects H2O2 removal by rat heart mitochondria. Arch. Biochem. Biophys. 2019, 662, 61–67. [CrossRef] [PubMed]

253. Veal, E.A.; Day, A.M.; Morgan, B.A. Hydrogen peroxide sensing and signaling. Mol. Cell 2007, 26, 1–14.

254. Mailloux, R.J. Mitochondrial Antioxidants and the Maintenance of Cellular Hydrogen Peroxide Levels. Oxid. Med. Cell. Longev. 2018, 2018, 7857251. [CrossRef] [PubMed]